<SEC-DOCUMENT>0001140361-23-053659.txt : 20231116
<SEC-HEADER>0001140361-23-053659.hdr.sgml : 20231116
<ACCEPTANCE-DATETIME>20231116161620
ACCESSION NUMBER:		0001140361-23-053659
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20231114
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231116
DATE AS OF CHANGE:		20231116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		231414797

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20014811_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:erna="http://eternatx.com/20231114" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_70bd02734fa24dfeb0114008727e8e44" contextRef="c20231114to20231114" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_98703841345b448eba9f48742151dfb6" contextRef="c20231114to20231114">0000748592</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20231114.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20231114to20231114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-14</xbrli:startDate><xbrli:endDate>2023-11-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_35234d1cfb4245ebaad41647342de055" contextRef="c20231114to20231114">8-K</ix:nonNumeric></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_65f8498b7a9b45c89ca42dc5344269aa" contextRef="c20231114to20231114" format="ixt:date-monthname-day-year-en">November 14, 2023</ix:nonNumeric></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_8db86f2708ef4b15ba52236765c5e44b" contextRef="c20231114to20231114">Eterna Therapeutics Inc.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_aad2f94da6574b45be5c7a8cdebedeb5" contextRef="c20231114to20231114" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_18cfa38c8a6f4d68b89711e9f60a8037" contextRef="c20231114to20231114">001-11460</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_db830d05ff594ddf9fadb9a7f68e32b7" contextRef="c20231114to20231114">31-1103425</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 33.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_01021a18288047c8bbe9ee0e4844106a" contextRef="c20231114to20231114">1035 Cambridge Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_13f9dcc78756407983eb1b188f353316" contextRef="c20231114to20231114">Suite 18A</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_423c1acd174d49fbb5a320b38f292f7e" contextRef="c20231114to20231114">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3e1128eef6dd481188edf4d2285e20e9" contextRef="c20231114to20231114">MA</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_8961b8ee0b094fba8bd1fa38317ce664" contextRef="c20231114to20231114">02141</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-style: italic;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_fdb2b3bf18cd49dc8b504c62ea30a3f3" contextRef="c20231114to20231114">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_87e56ece077a4346992fc6a4a4caf65c" contextRef="c20231114to20231114">582-1199</ix:nonNumeric></span></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
      provisions:</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_28cdec7e047d40b38d061a160c6c9305" contextRef="c20231114to20231114" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_34c83f3ba81446f3b9d277f945393d85" contextRef="c20231114to20231114" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_5fe0b17be813468598371a345c265fe6" contextRef="c20231114to20231114" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_cc13e1c15eed453f98aea676626cc99a" contextRef="c20231114to20231114" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 0.96%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 18.76%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Trading symbol</div>
          </td>

    <td style="width: 1%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c9de3d16f8a44682abc58249bb292acc" contextRef="c20231114to20231114">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 0.96%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 18.76%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_9c8ac18c648f43d98901644d4f0d138e" contextRef="c20231114to20231114">ERNA</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 1%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 38%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_5ea83905592641ab8668a993634299af" contextRef="c20231114to20231114" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
      Act of 1934:</div>

    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_ca6e82bf085d4680998d7612b97c2528" contextRef="c20231114to20231114" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On November 14<span style="font-weight: bold;">,</span> 2023, Eterna Therapeutics Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an
      Exclusive Amended and Restated License Agreement (the &#8220;A&amp;R Agreement&#8221;) with Factor Bioscience Limited (&#8220;Factor&#8221;) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023.&#160; The A&amp;R
      Agreement provides for, among other things, the expansion of the Company&#8217;s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as
      opposed to only permitting a direct sublicense).&#160; The A&amp;R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&amp;R Agreement and reduces the termination rights of Factor under the A&amp;R
      Agreement.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Dr. Matthew Angel, the Company&#8217;s President and Chief Executive Officer, is the co-founder, President, CEO, and a director of Factor Bioscience Inc.,
      which is the parent of Factor.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the A&amp;R Agreement is only a summary and is qualified in its entirety by reference to the full text of the A&amp;R
      Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01*.</div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
            </div>
          </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: center;">
            <div>
              <div style="font-weight: bold;">Description</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;"><a href="ef20014811_ex10-1.htm">10.1#*</a></div>
          </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Amended and Restated Exclusive License Agreement, dated November 14, 2023, by and between Factor Bioscience Limited and Eterna Therapeutics Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1" rowspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center;">104</div>
          </td>

    <td style="width: 1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 89%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
          </td>

  </tr>


</table>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"># Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an
        asterisk because such information is both not material and is the type that the Company treats as private or confidential.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">* Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain
        information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and
        Exchange Commission or its staff upon request.</div>

      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
      duly authorized.</div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 50.28%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-variant: small-caps;">Eterna Therapeutics Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 50.28%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">Dated: November 16<span style="color: rgb(0, 0, 0);">, 2023</span></div>
          </td>

    <td style="width: 3.82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left;">By:</div>
          </td>

    <td style="width: 45.44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;/s/ Matthew Angel<br />
          </td>

    <td style="width: 1.01%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 3.82%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 45.44%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1" colspan="2">
            <div style="text-align: left;">Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
    </div>

    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20014811_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 10.1</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the
    type of information that the company treats as private or confidential.</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>&#160;AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT</u></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Agreement</u></font>&#8221;)
    is entered into as of this November 14, 2023 (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>A&amp;R Effective Date</u></font>&#8221;), by and between Factor Bioscience Limited, a company organized and existing under the laws of
    Ireland (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensor</u></font>&#8221;), and Eterna Therapeutics Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee</u></font>&#8221;). Licensor and Licensee may each be referred to in this Agreement individually as a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Party</u></font>&#8221; and collectively as the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Parties</u></font>.&#8221;</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Licensor and Licensee previously entered into that certain Exclusive License Agreement dated February 20, 2023, as amended by that certain
    First Amendment to Exclusive License Agreement dated July 12, 2023 (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Original Agreement</u></font>&#8221;), pursuant to which Licensor granted Licensee certain rights to certain
    Licensed Patents (as such term was defined in the Original Agreement); and</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Parties desire to amend and restate the Original Agreement;</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and
    sufficiency of which are hereby acknowledged, the Parties agree as follows:</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 1</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Definitions</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Unless otherwise specifically provided herein, the following terms, when used with a capital letter at the beginning, will have the following meanings:</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Affiliate</u></font>&#8221; means, with respect to a Party, a person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of this definition, the word
        &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management
        and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise. For the purposes of this definition and this Agreement, and for the avoidance of doubt, (a) Factor
        Bioscience Limited, Factor Bioscience Pty Ltd, Factor Bioscience LLC, and Factor Bioscience Inc. (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Factor Bio Entities</u></font>&#8221;) are each deemed not to be
        Affiliates of any of Eterna Therapeutics Inc., Eterna Therapeutics LLC, and Novellus Therapeutics Limited (collectively, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Eterna Entities</u></font>&#8221;), and (b) the Eterna
        Entities are each deemed not to be Affiliates of any of the Factor Bio Entities.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Agreement</u></font>&#8221; has the meaning set forth in the Preamble.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Applicable Law</u></font>&#8221; means all statutes, ordinances, regulations, rules or orders of any kind whatsoever of any agency, bureau, branch, office, court, commission, authority, department, ministry, official or other
        instrumentality of, or being vested with public authority under any law of, any country, state or local authority or any political subdivision thereof, or any association of countries that may be in effect from time to time and applicable to the
        activities contemplated by this Agreement.</font></font></div>
  <div style="text-align: justify;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.4.</font><font style="font-size: 10pt;">&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Commercially Reasonable Efforts</u></font>&#8221; means, with respect to the performance of activities hereunder by or on behalf of Licensee, the carrying out of such activities using commercial and business efforts and resources comparable
        to the efforts and resources that an entity engaged in out-licensing of technology similar to the inventions disclosed in the Licensed Patents would typically devote to such activities.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidential Information</u></font>&#8221; means all Information disclosed by one Party to the other during the negotiation of or under this Agreement in any manner, whether orally, visually, electronically, in writing or in other tangible
        or intangible form, that relates to Licensed Patents, Licensed Know-How, Licensed Products, or this Agreement, and the business hereunder, including the identity of Sublicensees and potential Sublicensees, any sublicenses and fees associated
        therewith unless such information is subject to an exception described in <font style="font-family: 'Times New Roman';"><u>Section </u>8.6</font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Control</u></font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Controlled by</u></font>&#8221; means, in the context of a license to or ownership of Intellectual Property, the ability on the part of a Party to
        grant access to or a license or sublicense of such Intellectual Property as provided for herein without violating the terms of any agreement or other arrangement between such Party and any third party existing at the time such Party would be
        required hereunder to grant such access or license or sublicense.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Cover</u></font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Covered</u></font>&#8221; means that the use, manufacture, sale, offer for sale, research, development, commercialization, importation or other
        commercial exploitation of the subject matter in question by an unlicensed entity: (a) would infringe an issued Valid Claim (or, in the case of a pending Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue in
        its then-current form) of a Licensed Patent, or (b) incorporates, uses, or otherwise relies upon the Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Existing License Agreements</u></font>&#8221; means each agreement set forth on <u><font style="font-family: 'Times New Roman';">Schedule 1.8</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Existing Opportunities</u></font>&#8221; means the Opportunities set forth on <u><font style="font-family: 'Times New Roman';">Schedule 1.9</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Expiration Date</u></font>&#8221; means November 22, 2027.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Exploit</u></font>&#8221; and &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Exploitation</u></font>&#8221; mean to research, develop, make, have made, manufacture, use, sell, have sold, offer for sale, commercialize,
        distribute, import and/or export.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Field</u></font>&#8221; means all human and veterinary uses. For the avoidance of doubt, the Field does not include agricultural uses.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Identify</u></font>&#8221; means with respect to an Opportunity and a third party, the execution of a term sheet between Licensee and such third party for such Opportunity.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.14.</font><font style="font-size: 10pt;">&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Improvement(s)</u></font>&#8221; means any invention, discovery, advancement, development, or creation which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensor, Licensee, any Sublicensee, or
        any of their respective Affiliates (or any of their respective personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) them); (b) is
        not an Independent Invention; and (c) is an improvement, modification or enhancement to one or more of the inventions disclosed in the Licensed Patents and/or utilizes, incorporates, or reads upon any element of one or more of the inventions
        disclosed in the Licensed Patents and/or is invented, developed, authored, created, or reduced to practice using one or more of the inventions disclosed in the Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.15.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Improvement Patents</u></font>&#8221; means the Patents claiming any of the Improvements, and any reissue, divisional, continuation, continuation-in-part or reexamination certificate thereof. During the Term, all Improvement Patents shall
        be set forth in <u><font style="font-family: 'Times New Roman';">Schedule 1.21</font></u>, as updated from time to time pursuant to <u><font style="font-family: 'Times New Roman';">Section 8.1.3</font></u>.</font></font></div>
  <div style="text-align: justify;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.16.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Independent Invention</u></font>&#8221; means any invention, discovery, advancement, development, or creation, which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of Licensee or an Affiliate of
        Licensee (or any of the personnel or agents of Licensee or an Affiliate of Licensee, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign inventions to) Licensee or
        an Affiliate of Licensee); (b) does not utilize, incorporate, or read upon any element of the inventions disclosed in the Licensed Patents and is not Covered by a Valid Claim; and (c) is not invented, developed, authored, created, or reduced to
        practice by Licensor (or Licensor&#8217;s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign inventions to) Licensor).</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.17.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Information</u></font>&#8221; means all information, know-how, data, results, technology, materials, business or financial information of any type whatsoever, in any tangible or intangible form, provided by or on behalf of one Party to the
        other Party, either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this Agreement, or that otherwise relates to the Licensed Patents, whether disclosed orally, visually,
        electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices, processes, ideas, research plans, antibodies, small molecules, compounds, targets, biological and chemical formulations,
        structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to
        the disclosing Party or to its present or future products, sales, suppliers, customers, employees, investors or businesses.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.18.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Intellectual Property</u></font>&#8221;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>means all (a) Patents; (b) trademarks, service marks, trade dress, Internet domain names, logos, trade names and corporate names
        and registrations and applications for registration thereof; (c) copyrights and registrations and applications for registration thereof, including all moral rights; (d) Know-How; (e) other proprietary rights relating to any of the foregoing
        (including remedies against infringement thereof and rights of protection of interest therein under the laws of all jurisdictions); and (f) copies and tangible embodiments thereof.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.19.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;<u>Know-How</u>&#8221;</font> means all Information, inventions, trade secrets and confidential information, whether patentable or non-patentable and whether or not reduced to practice, know-how, show how, manufacturing and product processes
        and techniques, research and development information, notebooks, formulae, diagrams, technical and engineering specifications, business and marketing plans and customer and supplier lists and other information.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.20.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;<u>Licensed Know-How</u>&#8221;</font> means all Know-How Controlled by Licensor and/or its Affiliates that is necessary or reasonably useful to practice any invention taught or claimed in the Licensed Patents (including Exploiting Licensed
        Products)<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> [*]</font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.21.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensed Patents</u></font>&#8221; means all Patents Controlled by Licensor and/or its Affiliates on the A&amp;R Effective Date and/or during the Term of this Agreement, including the patents and patent applications set forth on <u><font style="font-family: 'Times New Roman';">Schedule 1.21</font></u><font style="font-family: 'Times New Roman';"><u>.</u></font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.22.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensed </u><u>Product</u>&#8221;</font> means any product Covered by the Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.23.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Opportunity</u></font>&#8221; means with respect to any third party, the opportunity to grant a sublicense of rights granted to Licensee under this Agreement with respect to, or under the applicable Licensed Patent(s) and/or Licensed
        Know-How to such third party.</font></font></div>
  <div style="text-align: justify;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.24.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Original Effective Date</u></font>&#8221; means February 20, 2023.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.25.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent</u></font>&#8221; means any patent and provisional and non-provisional patent application, together with all priority application, addition, division, continuation, continuations-in-part, substitution, and reissue claiming priority
        thereto, as well as any reexamination, post-grant proceeding, utility model, certificate of invention and design patents, applications, registrations and applications, extension, registration, patent term extension, supplemental protection
        certificate, renewal and the like with respect to any of the foregoing and all foreign counterparts thereof.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.26.</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Expenses</u></font>&#8221; means all reasonable fees, costs, and expenses (including attorneys&#8217; fees) paid or incurred in the preparation, filing, prosecution, issuance, and maintenance of the Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.27.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;<u>Proposed Publication</u>&#8221;</font> has the meaning set forth in<u> <font style="font-family: 'Times New Roman';">Section 2.4.2</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.28.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Pursue</u></font>&#8221; means with respect to an Opportunity and a third party, the process up until and including signing of a definitive agreement between Licensee and such third party for the Opportunity.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.29.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;<u>Review Period</u>&#8221;</font> has the meaning set forth in <u><font style="font-family: 'Times New Roman';">Section 2.4.2</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.30.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Subcontractor</u></font>&#8221; means any third party, or Licensee, as applicable, engaged on a fee-for-service basis via a written contract and acting solely as a contract manufacturer, contract research organization, contract development
        and manufacturing organization, distributor, and the like.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.31.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicense Fees</u></font>&#8221; means consideration made to Licensee or any of its Affiliates (including any Wholly-Owned Subsidiaries) as consideration for a sublicense of, or other right, license, option, privilege, or immunity with
        respect to, any Licensed Product or any of the rights to the Licensed Patents or Licensed Know-How granted to Licensee hereunder, or for the provision of services as contemplated by <font style="font-family: 'Times New Roman';"><u>Section </u>3.1</font>,
        including license fees, upfront payments, milestone payments, and royalties payable on sales of Licensed Products. For the avoidance of doubt, Sublicense Fees shall include payments made by any Sublicensee to Licensee that are required by an
        agreement (or collection of agreements) between Licensee and a Sublicensee, wherein said agreement (or collection of agreements) includes the granting of any rights under any of the Licensed Patents or Licensed Know-How or the sublicensing of any
        rights under any of the Licensed Patents or Licensed Know-How, or the provision of services as contemplated by <font style="font-family: 'Times New Roman';"><u>Section </u>3.1</font>, including, up-front payments, milestone payments, and royalty
        payments payable on sales of Licensed Products. To the extent Licensee or its Affiliates receives any non-cash consideration, including equity, under or in connection with a sublicense or the provision of services as contemplated by <font style="font-family: 'Times New Roman';"><u>Section </u>3.1</font>, in either case which would be considered &#8220;Sublicense Fees&#8221;, then the fair market value of such non-cash consideration shall be as reasonably determined by the Parties and shall
        be treated as &#8220;Sublicense Fees&#8221; (or if such fair market value cannot be reasonably determined by the Parties, Licensor shall be entitled to such applicable percentage of such non-cash consideration in accordance with <font style="font-family: 'Times New Roman';"><u>Section </u>5.1</font>). Notwithstanding the foregoing, &#8220;Sublicense Fees&#8221; shall exclude (a) fees and commissions to be paid by or to a broker or financial advisor in connection with obtaining a sublicense, as long as the
        fee or commission is ten percent (10%) or less of the Sublicense Fee (and provided that Licensee shall at all times negotiate in good faith to minimize such fees), (b) consideration for the issuance of equity interests in Licensee (including rights
        to receive equity interests such as conditional equity, warrants, or convertible debt) but only to the extent the amount paid for such equity or equity interests (i) does not exceed its fair market value, and (ii) is disclosed to Licensor, and (c)
        payments of loans or other debt obligations (it being understood that any such amounts which are forgiven shall be deemed Sublicense Fees) on arms&#8217; length terms; provided that the exclusions in clauses (a) &#8211; (c) shall not apply if the reason for
        such excluded payments is to avoid payments in respect of Sublicense Fees to the Licensor as contemplated under <font style="font-family: 'Times New Roman';"><u>Section </u>5.1</font> hereof.</font></font></div>
  <div style="text-align: justify;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.32.</font><font style="font-size: 10pt;">&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicensee</u></font>&#8221; means any third party to which Licensee or a Wholly-Owned Subsidiary grants a sublicense pursuant to <u><font style="font-family: 'Times New Roman';">Section 2.2</font></u>, whether directly or indirectly, but
        excluding (i) Licensee, (ii) any Subcontractor, and (iii) any Affiliate or Wholly-Owned Subsidiary of Licensee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.33.</font><font style="font-size: 10pt;">&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Success Milestone</u></font>&#8221; means actual receipt by Licensor of at least six million U.S. dollars ($6,000,000) paid by Licensee pursuant to <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u> and <u><font style="font-family: 'Times New Roman';">Section 7.1</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.34.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Territory</u></font>&#8221; means worldwide.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.35.</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Valid Claim</u></font>&#8221; means: (a) any currently pending claim of a patent application within the Licensed Patents<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, which has not been abandoned; </font>or (b) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">a claim of a</font> granted and unexpired and unlapsed patent within the Licensed Patents that (i) has not been revoked, held invalid, or declared unpatentable or unenforceable by a
        decision of a court or other governmental agency of competent jurisdiction that is unappealable or unappealed in the time allowed for appeal; (ii) has not been rendered or admitted to be invalid, abandoned or unenforceable through reissue or
        disclaimer or otherwise; or (iii) has not been lost through an interference proceeding. However, if a claim of a pending patent application shall not have issued within seven (7) years after the filing date of such pending patent application, such
        claim shall not constitute a Valid Claim for purposes of this Agreement.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.35</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Wholly-Owned Subsidiary</u></font>&#8221; means any entity which is directly or indirectly wholly-owned by Licensee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 2</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Licenses</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>License Grant</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to the terms and conditions of this Agreement (including <u><font style="font-family: 'Times New Roman';">Section 2.4</font></u>, <u><font style="font-family: 'Times New Roman';">Section 6.2.1</font></u>, and <u><font style="font-family: 'Times New Roman';">Section 6.2.4</font></u>), Licensor hereby grants to Licensee and its Wholly-Owned Subsidiaries an exclusive (even as to
    Licensor), non-transferrable (except in accordance with <u><font style="font-family: 'Times New Roman';">Section 11.2</font></u>), royalty-bearing license, with the right to grant sublicenses pursuant to <u><font style="font-family: 'Times New Roman';">Section 2.2</font></u>, under the Licensed Patents and Licensed Know-How to Exploit Licensed Products in the Territory in the Field during the Term, <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>,
    that the license granted to any Wholly-Owned Subsidiary may be declined by such Wholly-Owned Subsidiary, and in such circumstances, Licensee may sublicense such rights thereunder to such Wholly-Owned Subsidiary without the need to comply with <u><font style="font-family: 'Times New Roman';">Section 2.2</font></u>, provided that (i) such sublicense is granted pursuant to a written agreement, (ii) Licensee will be responsible for requiring compliance by such Wholly-Owned Subsidiary of such written
    agreement and for reasonably enforcing the terms of such written agreement, (iii) subject to <u><font style="font-family: 'Times New Roman';">Section 8.6</font></u>, Licensee will provide Licensor with a complete, confidential copy of each such
    written agreement executed by Licensee and any amendments thereto within thirty (30) days of the execution of said written agreement or any such amendments thereto and will promptly notify Licensor of the termination of any such written agreement, (iv)
    such Wholly-Owned Subsidiary shall at all times remain subject to <u><font style="font-family: 'Times New Roman';">Section 6.2.4</font></u> hereof, and (v) such Wholly-Owned Subsidiary shall not further sublicense any of the rights granted to it under
    such written agreement to Licensee, any Affiliate of Licensee, or any other Wholly-Owned Subsidiary, without Licensor&#8217;s consent.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Sublicensing</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(including for purposes of this </font><u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section </font><font style="font-family: 'Times New Roman';">2.2</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, its Wholly-Owned Subsidiaries that have not declined a license or
      have otherwise been granted a sublicense by Licensee pursuant to <u>Section </u></font><u><font style="font-family: 'Times New Roman';">2.1</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">)</font> has the right to
    sublicense the rights granted to it under <u><font style="font-family: 'Times New Roman';">Section 2.1</font></u>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">i.e</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">., without Licensor&#8217;s prior written consent) through multiple tiers to any third party that would qualify as a Sublicensee to any Sublicensee
      pursuant to a written agreement, subject to the following (each, a &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Sublicense Agreement</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;): (a) </font>the sublicense is in writing, and includes other industry standard provisions for the development and/or commercialization of Licensed Products, including reasonable diligence requirements, patent marking requirements,
    development and commercialization reporting requirements, and insurance requirements, in each case if and to the extent such provisions would customarily be included in such a sublicense based on then-current industry standards; (b) the terms of the
    Sublicense Agreement are consistent with applicable terms and conditions of this Agreement, including, <u><font style="font-family: 'Times New Roman';">Section 7.6</font></u>, as well as the Existing License Agreements; (c) the sublicense was
    negotiated by Licensee in good faith, for a proper commercial purpose, on reasonable arm&#8217;s-length commercial terms and is not for all or substantially all rights granted to it under <u><font style="font-family: 'Times New Roman';">Section 2.1</font></u>
    (d) the Sublicense Agreement names Licensor as a third-party beneficiary thereof; and (e) the Sublicensee has, or has the ability to acquire, adequate resources (including scientific, technical and financial) to perform its obligations under such
    sublicense, as reasonably determined by Licensee at the time of entry into the sublicense, <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that Licensee may not grant any such sublicense to any third
    party (i) (A) in case of a public company, that is valued at thirty million dollars ($30,000,000) or less (e.g., by market capitalization or shareholder equity reflected on such company&#8217;s balance sheet) or (B) in case of a private company, that does
    not have at least seven million dollars ($7,000,000) in cash, in each case, as of the time of entering into the Sublicense Agreement, (ii) that is a non-practicing entity (<font style="font-family: 'Times New Roman'; font-style: italic;">e.g</font>.,
    patent troll) that does not conduct any Exploitation activities, (iii) in which Licensee or its Affiliates collectively own or control more than five percent (5%) of such entity or (iv) for which a purpose of entering into such sublicense is to avoid
    payments to Licensor as contemplated under <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u> hereof, including sublicenses to a related party entity, in each case (i) through (iii), without the prior written consent of Licensor,
    which shall not be unreasonably withheld, conditioned, or delayed. In each case, Licensee will be responsible for requiring compliance by the applicable counterparty(ies) (i.e., Sublicensees) of such Sublicense Agreements entered into by Licensee and
    for reasonably enforcing the terms of such Sublicense Agreements, including, requiring such applicable Sublicensee(s) to make any of the payments provided for thereunder. Subject to <font style="font-family: 'Times New Roman';"><u>Section </u>8.6</font>,
    Licensee will provide Licensor with a complete, confidential copy of each such Sublicense Agreement executed by Licensee and any amendments thereto within thirty (30) days of the execution of said Sublicense Agreement or any such amendments thereto
    (except to the extent that a Sublicensee requires redaction of their confidential information that is not necessary to confirm compliance with this Agreement) and will promptly notify Licensor of the termination of any such Sublicense Agreement.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Subcontracting</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Sublicensee (and Licensee, but only to the extent: (i) Licensee is engaged by a Sublicensee as a Subcontractor pursuant to this <u><font style="font-family: 'Times New Roman';">Section 2.3</font></u> or (ii) necessary for Licensee to build capacity pursuant to <font style="font-family: 'Times New Roman';"><u>Section 3.1</u></font> to perform services for Sublicensees as a
    Subcontractor pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font>) has the right to sublicense the rights granted to it under <u><font style="font-family: 'Times New Roman';">Section 2.2</font></u>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(or, to the extent Licensee</font> conducts activities necessary for Licensee to build capacity pursuant to <font style="font-family: 'Times New Roman';"><u>Section 3.1</u></font> to
    perform services for Sublicensees as a Subcontractor pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, <u>Section 2.1</u>, </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">i.e</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">., in either case without Licensor&#8217;s prior written consent, subject to the terms of this
      Agreement, including <u>Section </u></font><u><font style="font-family: 'Times New Roman';">6.2.4</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">) to any Subcontractor pursuant to a written agreement</font>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">to subcontract the responsibility to perform, on such Sublicensee&#8217;s behalf, activities for which it is responsible under the applicable Sublicense Agreement (or to the extent Licensee</font>
    conducts activities necessary for Licensee to build capacity pursuant to <font style="font-family: 'Times New Roman';"><u>Section 3.1</u></font> to perform services for Sublicensees as a Subcontractor pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, on Licensee&#8217;s behalf, activities </font>necessary for Licensee to build capacity pursuant to <font style="font-family: 'Times New Roman';"><u>Section


        3.1</u></font> to perform services for Sublicensees as a Subcontractor pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">), </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>provided, however</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, that </font>(a) the terms of such agreement are consistent with
    applicable terms and conditions of this Agreement, as well as the Existing License Agreements, and (b) as between the Parties, Licensee shall at all times remain responsible for, and shall be liable under this Agreement with respect to, any breach of
    this Agreement resulting directly or indirectly from the performance, or failure to perform, by any such Subcontractors.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Retained Rights; Requirements</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.4.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Retained Rights</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any and all licenses granted hereunder are subject to (a) Licensor&#8217;s and its Affiliates&#8217; right to use and otherwise perform activities, and to permit
    academic, government, and not-for-profit institutions or agencies to use and otherwise perform activities, under the Licensed Patents and Licensed Know-How (i) in the Field for non-commercial research, academic, educational, and all other
    non-commercial purposes, and (ii) outside of the Field for all commercial and non-commercial purposes, (b) Licensor&#8217;s and its Affiliates&#8217; right to use and otherwise perform activities under the Licensed Patents and Licensed Know-How (i) to conduct
    research and development activities for Licensor and/or its Affiliates on behalf of itself (or themselves) to generate Improvements and other new Patents and Know-How (which for clarity will be licensed to Licensee pursuant to <u><font style="font-family: 'Times New Roman';">Section 2.1</font></u> hereof), (ii) for the provision of services to Sublicensees pursuant to <u><font style="font-family: 'Times New Roman';">Section 3.1</font></u>, and (iii) with the consent of Licensee,
    for the provision of services to other third parties, including commercial contract research, development or manufacturing services, and (c) any licenses or other rights granted by Licensor to third parties under the Existing License Agreements. All
    rights and interests not expressly granted to Licensee under this Agreement are reserved by Licensor (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Reserved Interests</u></font>&#8221;) for itself, its licensors, and other
    licensees and sublicensees. It shall not be a breach of this Agreement for Licensor, acting directly or indirectly, to exploit its Reserved Interests in any manner anywhere in the Territory.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; text-indent: 4.5pt; margin-left: 103.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.4.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Right to Publish</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Subject to this <u><font style="font-family: 'Times New Roman';">Section 2.4.2</font></u>, any and all licenses granted hereunder are subject to the
    right of Licensor to review publication of scientific findings related to the Licensed Patents and Licensed Know-How. If Licensee desires to submit any publication related to the Licensed Patents or Licensed Know-How or that would otherwise disclose
    Confidential Information of Licensor or any patentable information related to Licensed Patents or Licensed Know-How (each, a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Proposed Publication</u></font>&#8221;), Licensee will provide
    Licensor with prior written notice of such Proposed Publication and a copy of such Proposed Publication. Licensor will use reasonable efforts to complete its review of such Proposed Publication promptly, and in any event will complete its review within
    thirty (30) days of receipt of the Proposed Publication (or ten (10) days in case of abstracts) (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Review Period</u></font>&#8221;), provided that Licensor shall be deemed to have given
    its consent if Licensor does not complete its review within the Review Period. Licensor shall notify Licensee of any Licensor Confidential Information contained in such Proposed Publication and, in response to such notification, Licensee will promptly
    delete any Licensor Confidential Information from the Proposed Publication that a Licensor has identified during the Review Period. Licensor will have the right to delay submission of the Proposed Publication for up to an additional thirty (30) days if
    Licensor determines, in its sole discretion, that publication of the Proposed Publication would have negative effects on Licensor&#8217;s patent rights. In the event that Licensor decides to delay submission of the Proposed Publication, Licensor shall inform
    Licensee of such decision within the Review Period, and the Parties shall reasonably cooperate in order to resolve any concerns with the Proposed Publication within such review period (as may be extended if the publication has already been submitted).</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
    <div style="text-align: left; text-indent: 4.5pt; margin-left: 103.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.4.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>U.S. Federal Funding</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any and all licenses granted under patents supported by U.S. federal funding are subject to the rights, conditions, and limitations imposed by U.S.
      law (see 35 U.S.C. &#167;202 <font style="font-family: 'Times New Roman';"><u>et seq</u></font>. and regulations pertaining thereto), including: (i) the royalty-free, non-exclusive license granted to the U.S. government; and (ii) the requirement that any
      products covered by an issued claim and sold in the U.S. will be substantially manufactured in the United States. Licensee agrees to inform Licensor of those Improvements that are developed, reduced to practice or invented by Licensee&#8217;s personnel and
      agents or the personnel or agents of Licensee&#8217;s Affiliates or Sublicensees (or that are Controlled by Licensee or Licensee&#8217;s personnel or agents or the personnel or agents of Licensee&#8217;s Affiliates or Sublicensees) during the Term and beyond with the
      support (either entirely or in part) of U.S. federal funding, and to provide all information and documentation to Licensor that Licensor may request to secure patent rights for those inventions, including, but not limited to, grant numbers, contract
      numbers, and names of granting and contracting institutions and organizations.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 3</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Provision of Services; Tech Transfer; Joint Steering Committee; Reservation of Rights</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 40.3pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Provision of Services</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">It is anticipated that the Sublicensees may require research and development services to be provided by Licensor. To the extent Licensor has the
    expertise and bandwidth and can provide such services, Licensor shall use commercially reasonable efforts to provide such services to Sublicensees on a commercially reasonable and arm&#8217;s length basis as requested by the Sublicensees on terms to be
    negotiated in good faith by Licensor and such Sublicensees. At Licensee&#8217;s discretion, subject to <u><font style="font-family: 'Times New Roman';">Section 6.2.4</font></u>, it may over time build capacity to provide such services to Sublicensees to
    supplement Licensor&#8217;s capacity and, pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font>, shall provide such services to Sublicensees on a commercially reasonable and arm&#8217;s length basis as may be requested by
    Sublicensees or Licensor. Details of the provision of such services by both Parties will be shared at the Joint Steering Committee as set forth in <u><font style="font-family: 'Times New Roman';">Section 3.3</font></u>.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 40.3pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Tech Transfer</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Within ninety (90) days of the A&amp;R Effective Date, Licensor shall use good faith efforts to transfer to Licensee all Licensed Know-How to be used in
    accordance with this Agreement, to the extent not previously transferred to Licensee, and shall continue to use good faith efforts to provide reasonable assistance with technical transfer throughout the Term, including the technical transfer of
    Licensed Know-How relating to Improvements and other new inventions Controlled by Licensor or its Affiliates during the Term, as reasonably requested by Licensee.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 40.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Joint Steering Committee</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Parties shall establish a joint steering committee (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Joint Steering Committee</u></font>&#8221;)


    composed of two (2) members from each Party (or such larger number of members agreed to by the Parties, provided each Party has an equivalent number of participating members). The Joint Steering Committee shall meet on a quarterly basis to share
    information, views and discuss (a) the status of sublicenses and Sublicense Agreements; (b) needs of Sublicensees for services and the potential provision of services by Licensor and/or Licensee pursuant to <u><font style="font-family: 'Times New Roman';">Section 3.1</font></u>, including the bandwidth and scope of resources required, and coordination of the Parties in providing such services; (c) potential Sublicensees; (d) new Patents and Know-How Controlled by Licensor and its Affiliates
    after the Original Effective Date, including Improvement Patents; (e) the status of patent prosecution of Licensed Patents; (f) the status of technical transfer, if any, pursuant to <u><font style="font-family: 'Times New Roman';">Section 3.2</font></u>;
    and (g) identification of third parties infringing the Licensed Patents and strategy related thereto. While the Joint Steering Committee is not a decision-making body, each Party will consider in good faith the views of the other Party.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 40.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>No Grant of Other Technology or Patent Rights</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party understands and acknowledges that the other Party owns its own Intellectual Property and all rights therein. Except as otherwise expressly
    provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest or license, or be deemed to obtain any ownership interest or license, in or to any technology, know-how, patents,
    patent applications, products, or materials of the other Party, including, but not limited to, items Controlled or developed by the other Party, at any time pursuant to this Agreement. This Agreement does not create, and shall under no circumstances be
    construed or interpreted as creating, an obligation on the part of either Party to grant any license to the other Party other than as expressly set forth herein. Any further contract or license agreement between Licensor and Licensee shall be in
    writing. No licenses are implied by Licensor to Licensee, except as specifically stated in this Agreement. Except as explicitly set forth in this Agreement, Licensor shall not be deemed by estoppel or implication to have granted Licensee any license or
    other right to any Intellectual Property of Licensor or its Affiliates.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 4</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Diligence</u></div>
  <div style="font-size: 10pt; margin-left: 36pt;">&#160;4.1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Licensee Responsibilities</u></font><font style="font-size: 10pt;">.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.1.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Licensee will use Commercially
        Reasonable Efforts to Identify and Pursue Opportunities.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.1.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee shall provide Licensor
        semi-annual written updates on Licensee&#8217;s activities hereunder, and on each Sublicensee&#8217;s Licensed Product development and commercialization activities in the Field in the Territory, beginning as of the date of the applicable Sublicense Agreement,
        which updates shall be provided to Licensor at least every six (6) months during the Term and upon Licensor&#8217;s reasonable request therefor, and Licensor shall have the right to reasonably request additional information regarding Licensee&#8217;s (or each
        Sublicensee&#8217;s) progress in this regard. Such updates will include a reasonably detailed summary of the activities undertaken by or on behalf of Licensee since the last report was delivered; and a reasonably detailed summary of the activities to be
        undertaken by or on behalf of Licensee (or each applicable Sublicensee) during the next twelve (12)-month period and the expected timing of such activities (including the estimated dates of initiation and completion of such activities).</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 5</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Consideration; Records &amp; Reports</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Royalties on Sublicense Fees</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee shall, within thirty (30) days of receipt of any Sublicense Fees, (a) pay to Licensor twenty percent (20%) of any such Sublicense Fees received
    in connection with any Existing Opportunities or Opportunities Identified during the Term (which, for clarity, includes both the Initial Term and the Renewal Term), and (b) provide to Licensor a report specifying the source and nature of the Sublicense
    Fees, the gross amount of Sublicense Fees received, any applicable fees, credits or deductions permitted pursuant to this Agreement, and the net amount of Sublicense Fees payable to Licensor. For the purpose of converting the local currency in which
    any Sublicense Fees arise into US dollars, the rate of exchange to be applied shall be the rate of exchange in effect on the last business day before such Sublicense Fees were received by Licensee as reported in the Wall Street Journal. Licensee shall
    pay in U.S. dollars all amounts due to Licensor pursuant to this Agreement. All payments due to Licensor hereunder shall be made by wire transfer of immediately available funds into an account designated by Licensor.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Audit and Inspection Rights</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee and its Affiliates and Sublicensees will maintain complete and accurate records in sufficient detail to permit Licensor to confirm the accuracy
    of the calculation of payments under this Agreement. Upon reasonable prior notice, such records shall be available during regular business hours (without undue disruption of Licensee&#8217;s business) for a period of three (3) years from the end of the
    calendar year to which they pertain for examination by an independent accountant selected by the Licensor and reasonably acceptable to Licensee, for the sole purpose of verifying the accuracy of the reports and payments furnished by Licensee pursuant
    to this Agreement. Audits may not be requested more than once per year, and no period may be audited more than once. Any such auditor shall enter into a confidentiality agreement with Licensee, and shall not disclose Licensee&#8217;s Confidential
    Information, except to the extent such disclosure is necessary to verify the accuracy of the reports furnished by Licensee or the amount of payments due by Licensee to Licensor under this Agreement. The auditor may not be compensated on a commission,
    bonus, or any other payment that depends on the result of the audit or amounts due or paid as a result of the audit. Any undisputed amounts shown to be owed but unpaid shall be paid within thirty (30) days from the accountant&#8217;s report, plus interest
    (as set forth in <font style="font-family: 'Times New Roman';"><u>Section </u>5.4</font>) from the original due date. Licensor shall bear the full cost of such audit.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Taxes</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of
    the Parties under this Agreement. The Parties agree to cooperate with one another and use commercially reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of payments made by a Party to the other Party under this
    Agreement. To the extent Licensee is required to deduct and withhold taxes on any payment to Licensor hereunder, Licensee shall pay the amounts of such taxes to the proper governmental authority in a timely manner and promptly transmit to Licensor an
    official tax certificate or other evidence of such withholding sufficient to enable Licensor to claim such payment of taxes. Licensor shall provide the Licensee with any tax forms that may be reasonably necessary in order for the Licensee to not
    withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes, value added
    taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late Payment</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If Licensor does not receive payment of any sum due to it on or before the due date (each, a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late Payment</u></font>&#8221;), Licensee shall pay to the applicable Licensor an amount equal to five percent (5%) of such Late Payment (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Late Payment Penalty</u></font>&#8221;),
    and such Late Payment shall not be considered paid in full until Licensor has received from Licensee both the full amount of such Late Payment and the Late Payment Penalty. For the avoidance of doubt, payment by Licensee within thirty (30) days past
    the due date will not be considered a Late Payment subject to a Late Payment Penalty.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Maintenance Fees</u>.</font></font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Beginning on September 9, 2024, and on the ninth (9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day of each calendar month during the Term thereafter (which, for clarity, includes
    both the Initial Term and the Renewal Term), Licensee shall pay Licensor an amount equal to four hundred sixteen thousand six hundred sixty-seven U.S. dollars ($416,667).</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 6</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Warranties</u></div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u> <br>
    </u></div>
  <div style="font-size: 10pt; margin-left: 36pt;">&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">6.1&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Representations, Warranties and Covenants of Licensor</u></font><font style="font-size: 10pt;">.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that, as of the Original Effective Date, the Patents identified on <u><font style="font-family: 'Times New Roman';">Schedule 1.21</font></u> are all the Patents owned or licensed by Licensor in the Territory. Licensor hereby represents
        and warrants to Licensee that, as of the A&amp;R Effective Date, it is the sole and exclusive owner or licensee of the Licensed Patents, and it has the right, power and authority to grant the rights set forth in <u><font style="font-family: 'Times New Roman';">Section 2.1</font></u> of this Agreement. Licensor hereby covenants to Licensee that it will, during the Term, at Licensee&#8217;s reasonable request from time to time, update <u><font style="font-family: 'Times New Roman';">Schedule
            1.21</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that, as of the A&amp;R Effective Date and for the entire Term of this Agreement, the execution and performance of Licensor&#8217;s obligations under this Agreement do not conflict with, cause a default under, result in a breach of or violate
        any existing contractual obligation that may be owed by Licensor to any third party, including, any Affiliate of Licensor, nor will Licensor, during the Term of this Agreement, take any action, inaction or enter into agreement that would conflict
        with, cause a default under, result in a breach of or violate any existing contractual obligation that is owed to Licensee under this Agreement.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that it has full power and authority to execute, deliver and perform this Agreement and that this Agreement constitutes the legally binding and valid obligation of Licensor, enforceable in accordance with its terms, except as such
        enforcement may be limited by applicable bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that (i) there are no liens or other encumbrances on the Licensed Patents or any part thereof which would interfere with the rights granted to Licensee under this Agreement (which for clarity, are subject to the Existing License
        Agreements) and (ii) Licensor will not take any actions after the A&amp;R Effective Date of this Agreement that would be inconsistent with the rights granted Licensee under this Agreement.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that there is no action or suit pending against Licensor that questions the validity of this Agreement or the right of Licensor to enter into this Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>or
        consummate the transactions contemplated hereby.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.6</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby covenants to Licensee
        that during the Term, it will not grant any licenses under the Licensed Patents to any third party in the Field, without the prior consent of Licensee, provided that for clarity, Licensor shall have the right to grant licenses (i) in accordance
        with <u><font style="font-family: 'Times New Roman';">Section 2.4.1</font></u> of this Agreement without the consent of Licensee or (ii) to the extent set forth in the Existing License Agreements without the consent of Licensee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.7</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that, except as previously disclosed to Licensee there is no action or suit pending against Licensor that would adversely and materially impact Licensor&#8217;s business or operations.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.8</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that, except as previously disclosed to Licensee, there is no action or suit pending or threatened in writing against Licensor affecting the validity of the Licensed Patents or the ownership of Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.9</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        to Licensee that to its knowledge as of the date hereof, the Licensor&#8217;s practice of the Licensed Patents does not infringe any Intellectual Property of any third party.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.10</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby covenants to Licensee
        that it will, during the Term, inform Licensee of any Opportunities it becomes aware of, provided that doing so does not violate any obligation of confidentiality owed by Licensor to such third party, or will refer such Opportunities to Licensee.</font></font></div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.11</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby covenants to Licensee
        that it will not, during the Term, amend or modify any of the Existing License Agreements in a manner that would adversely affect or otherwise be in conflict with the rights granted to Licensee hereunder, without Licensee&#8217;s consent.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.1.12</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">Licensor hereby represents and warrants
        that as of the date hereof, it is not in breach of this Agreement and to its knowledge, Licensee is not in breach of this Agreement.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representations, Warranties and Covenants of Licensee</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby represents and warrants
        to Licensor that, as of the A&amp;R Effective Date, and for the entire Term of this Agreement, the execution and performance of Licensee&#8217;s obligations under this Agreement do not conflict with, cause a default under, or result in a breach of or
        violate any existing contractual obligation that may be owed by Licensee to any third party, including, any Affiliate of Licensee, nor will Licensee, during the Term of this Agreement, take any action, inaction or enter into agreement that would
        conflict with, cause a default under, result in a breach of or violate (i) any existing contractual obligation that is owed to Licensor under this Agreement or (ii) the terms of the Existing License Agreements.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby represents and warrants
        to Licensor that it has full power and authority to execute, deliver and perform this Agreement and that this Agreement constitutes the legally binding and valid obligation of Licensee, enforceable in accordance with its terms, except as such
        enforcement may be limited by applicable bankruptcy, moratorium and other laws affecting creditors&#8217; rights generally.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby represents and warrants
        to Licensor that there is no action or suit pending against Licensee or any of its Affiliates that questions the validity of this Agreement or the right of Licensee to enter into this Agreement or consummate the transactions contemplated hereby,
        and neither Licensee nor any of its Affiliates is a party to any litigation, arbitration, mediation or other similar legal proceeding.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Licensee, on behalf of itself and its
        Affiliates (including Wholly-Owned Subsidiaries), hereby covenants to Licensor that during the Term, except (i) to the extent necessary for Licensee to perform services for Sublicensees as a Subcontractor pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font>, and (ii) to the extent necessary for Licensee to build capacity pursuant to <font style="font-family: 'Times New Roman';"><u>Section 3.1</u></font> to perform services for Sublicensees as a
        Subcontractor pursuant to <font style="font-family: 'Times New Roman';"><u>Section 2.3</u></font>, Licensee, and its Wholly-Owned Subsidiaries will not use or practice the Licensed Patents or Licensed Know-How or Exploit any Licensed Product by
        itself or themselves or through any of their Affiliates (including through any Wholly-Owned Subsidiary), and for clarity, or through any successors or permitted assigns) absent a separate written agreement between Licensor and Licensee containing
        industry standard provisions, including economic terms, diligence requirements, patent marking requirements, development and commercialization reporting requirements, and insurance requirements, in each case if and to the extent such provisions
        would customarily be included in such an agreement based on then-current industry standards. The provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6.2.4</u></font> shall not apply to the granting of sublicenses by
        Licensee (or Wholly-Owned Subsidiaries, as applicable) under <font style="font-family: 'Times New Roman';"><u>Section 2.2</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Licensee hereby represents and warrants
        that as of the date hereof, it is not in breach of this Agreement and to its knowledge, Licensor is not in breach of this Agreement.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby covenants to Licensor
        that during the Term, it will not Pursue any Opportunity for which it does not have, in its reasonable estimation, resources sufficient to Pursue, including, without limitation, financial resources necessary to defend any claim, action or
        proceeding that may arise as a result of or in connection with such Pursuit.</font></font></div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.7</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby covenants to Licensor
        that during the Term, in the event of any dispute or disagreement between Licensor and Licensee as to the enforcement by Licensee of any Licensed Patent that Licensor reasonably believes could reasonably result in material irreparable harm to the
        validity or enforceability of one or more Licensed Patents, Licensee shall immediately cease such enforcement that is the subject of such dispute or disagreement, and shall not resume such enforcement unless and until such dispute or disagreement
        is resolved in accordance with <u><font style="font-family: 'Times New Roman';">Section 10</font>.</u></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.2.8</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee hereby covenants to Licensor
        that during the term of any Sublicense Agreement, Licensee will make Commercially Reasonable Efforts to enforce the provisions of such Sublicense Agreement.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Disclaimer</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except as expressly provided in <u><font style="font-family: 'Times New Roman';">Section 6.1</font></u>, nothing in this Agreement will be construed
    as:</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">a warranty or representation by
        Licensor as to the validity or scope of any of the Licensed Patents;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">a warranty or representation by
        Licensor that anything made, used, sold or otherwise disposed of under the licenses granted in this Agreement, or the practice of the Licensed Patents, will or will not infringe patents of third parties; or</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.3.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">an obligation of Licensor to bring or
        prosecute actions or suits against third parties for infringement of Licensed Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Express Disclaimer</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, LICENSOR IS PROVIDING THE LICENSED PATENTS AND LICENSED KNOW-HOW &#8220;AS IS.&#8221; EXCEPT AS EXPRESSLY PROVIDED
    IN THIS AGREEMENT,<font style="font-family: 'Times New Roman'; font-style: italic;">&#160;</font>NEITHER LICENSOR NOR LICENSEE MAKES ANY REPRESENTATIONS, EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF
    MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR AS TO THE VALIDITY OF ANY PATENTS, AND LICENSOR DOES NOT ASSUME ANY RESPONSIBILITY WHATSOEVER WITH RESPECT TO USE, SALE, OR OTHER DISPOSITION OF PRODUCTS
    INCORPORATING OR MADE BY USE OF LICENSED PATENTS OR LICENSED KNOW-HOW IN CONNECTION WITH THIS AGREEMENT.</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="font-size: 10pt; margin-left: 36pt;">6.5 &#160; &#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;"><u>Exclusion of Consequential and Other Direct Damages</u></font><font style="font-size: 10pt;">.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 31.7pt; font-family: 'Times New Roman'; font-size: 10pt;">TO THE FULLEST EXTENT PERMITTED BY LAW, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY OR ANY OTHER PERSON FOR ANY INJURY TO OR LOSS OF GOODWILL,
    REPUTATION, BUSINESS PRODUCTION, REVENUES, PROFITS, ANTICIPATED PROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR ENHANCED DAMAGES,
    WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH LOSS OR DAMAGE WAS FORESEEABLE
    AND THE PARTY AGAINST WHOM LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED REMEDY OF ITS ESSENTIAL PURPOSE. THE FOREGOING LIMITATIONS WILL NOT: (A) APPLY TO INFRINGEMENT BY
    A PARTY OF THE OTHER PARTY&#8217;S INTELLECTUAL PROPERTY RIGHTS OR A PARTY&#8217;S BREACH OF <u><font style="font-family: 'Times New Roman';">SECTIONS 8.6</font></u> OR <u><font style="font-family: 'Times New Roman';">11.13</font></u>, OR (B) LIMIT A PARTY&#8217;S
    INDEMNIFICATION OBLIGATIONS UNDER <u><font style="font-family: 'Times New Roman';">Section 9</font>.</u></div>
  <div style="text-align: justify; text-indent: 31.7pt; font-family: 'Times New Roman'; font-size: 10pt;"><u> </u><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 7</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Term and Termination</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The term of this Agreement (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Term</u></font>&#8221;) will begin on the A&amp;R
    Effective Date (provided that the Original Agreement will govern from February 20, 2023 until the A&amp;R Effective Date) and will expire, in its entirety, on the Expiration Date (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Initial


        Term</u></font>&#8221;) unless earlier terminated under the provisions of this <font style="font-family: 'Times New Roman';">Section 7</font>; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that, the
    Initial Term shall automatically extend for an additional five (5) years (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Renewal Term</u></font>&#8221;) if the Success Milestone has been met during the Initial Term, provided
    further that Licensee may, at any time during the Initial Term, pay Licensor an amount equal to the remaining amount necessary to meet the Success Milestone, and, upon actual receipt by Licensor of such payment during the Initial Term, the Success
    Milestone will be deemed to be met and the Initial Term shall automatically be extended by the Renewal Term upon the Expiration Date.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination by Licensor</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensor may, at its option, terminate this Agreement, upon written notice to Licensee after the occurrence of any of the following events or as
    otherwise provided in this Agreement:</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the provisions set forth in <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, any material breach of any of Licensee&#8217;s obligations under this Agreement, which includes any material breach of the express representations, warranties or covenants of Licensee set
        forth in <u><font style="font-family: 'Times New Roman';">Section 6.2</font></u>, which Licensee fails to remedy within ninety (90) days after receipt of written notice by Licensor of such material breach and Licensor&#8217;s demand that it be cured,
        and for avoidance of doubt, once the provisions of <u><font style="font-family: 'Times New Roman';">Section 10</font></u> are triggered, the ninety (90) day cure period is tolled pending the Alternative Dispute Resolution procedures and timing set
        forth in <u><font style="font-family: 'Times New Roman';">Section 10</font></u>;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">subject to the provisions set forth in
        <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, (a) the filing in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization
        or for an arrangement or for the appointment of a receiver or trustee or if Licensee is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing
        thereof, or if Licensee will propose or be a party to any dissolution or liquidation, or if Licensee will make an assignment for the benefit of its creditors, or (b) with twenty-four (24) hours written notice, if at any time Licensee voluntarily
        enters into proceedings for winding up or dissolution of business; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, if Licensee provides for the cure of all of its defaults under this Agreement (if
        any) and provides adequate assurance of its future performance of its obligations, then Licensor shall not have the right to terminate this Agreement pursuant to this <font style="font-family: 'Times New Roman';"><u>Section </u></font><u><font style="font-family: 'Times New Roman';">7.2.2(a)</font></u>;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">subject to the provisions set forth in
        <u><font style="font-family: 'Times New Roman';">Section 5</font></u>, Licensee&#8217;s failure to timely make any payment required to be made to Licensor as set forth in <u><font style="font-family: 'Times New Roman';">Section 5</font></u> or <u><font style="font-family: 'Times New Roman';">Section 8.2</font></u>, which Licensee fails to remedy within thirty (30) days after receipt of written notice by Licensor of such failure and Licensor&#8217;s demand that it be cured;</font></font></div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">any breach of Licensee&#8217;s obligations
        under <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u>, which Licensee fails to remedy within sixty (60) days after receipt of written notice by Licensor and Licensor&#8217;s demand that it be cured;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.5</font><font style="font-size: 10pt;"> &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee&#8217;s failure to comply with the
        obligation to <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">maintain in full force and effect the required insurance coverage in accordance with </font><u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section


          </font></u><font style="font-family: 'Times New Roman';"><u>9.3</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, </font>which Licensee fails to remedy within ninety (90) days after receipt of written
        notice by Licensor of such material breach and Licensor&#8217;s demand that it be cured; or</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.2.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the provisions set forth in
        <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, nothing in the foregoing subsections of this <u><font style="font-family: 'Times New Roman';">Section 7.2</font></u> shall prohibit Licensor from pursuing any and all rights
        and remedies it may have under this Agreement or at law or in equity. For the avoidance of doubt, Licensor&#8217;s right to terminate under <u><font style="font-family: 'Times New Roman';">Sections 7.2.3</font></u>, or <u><font style="font-family: 'Times New Roman';">7.2.4</font></u> shall not be subject to the provisions set forth in <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, shall not expire, and any such termination shall take effect upon written notice
        to Licensee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Termination by Licensee</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee may, at its option, terminate this Agreement in its entirety, upon written notice to the Licensor after the occurrence of any of the following
    events or as otherwise provided in this Agreement:</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">at any time, by giving at least one
        hundred and twenty (120) days prior written notice of such termination to Licensor;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the provisions set forth in <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, any material breach of any of Licensor&#8217;s obligations under this Agreement, which includes any material breach of the express representations, warranties or covenants of Licensor set
        forth in <u><font style="font-family: 'Times New Roman';">Section 6.1</font></u>, which Licensor fails to remedy within ninety (90) days after receipt of written notice by Licensee of such material breach and Licensee&#8217;s demand that it be cured,
        and for avoidance of doubt, once the provisions of <u><font style="font-family: 'Times New Roman';">Section 10</font></u> are triggered, the ninety (90) day cure period is tolled pending the Alternative Dispute Resolution procedures and timing set
        forth in <u><font style="font-family: 'Times New Roman';">Section 10</font></u>; or</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">subject to the provisions set forth in
        <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, the filing in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or
        for an arrangement or for the appointment of a receiver or trustee or if Licensor is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing
        thereof, or if Licensor will propose or be a party to any dissolution or liquidation, or if Licensor will make an assignment for the benefit of its creditors, or if at any time Licensor voluntarily enters into proceedings for winding up or
        dissolution of business; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, if Licensor provides for the cure of all of its defaults under this Agreement (if any) and provides adequate assurance of
        its future performance of its obligations, then the Licensee shall not have the right to terminate this Agreement pursuant to this <u><font style="font-family: 'Times New Roman';">Section 7.3.4</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.3.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the provisions set forth in
        <u><font style="font-family: 'Times New Roman';">Section 10</font></u>, nothing in the foregoing subsections of this <u><font style="font-family: 'Times New Roman';">Section 7.3</font></u> shall prohibit Licensee from pursuing any and all rights
        and remedies it may have under this Agreement or at law or in equity.</font></font></div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"> </font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Challenging Validity</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except to the extent unenforceable under Applicable Law in the Territory, Licensor may terminate this Agreement by written notice to Licensee in the
    event of a breach of <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u> by Licensee, its Affiliates or Sublicensees or in the event that Licensee or any of its Affiliates challenges, in any formal proceeding, the validity,
    patentability, enforceability, scope, construction or inventorship of any of the Licensed Patents or assists any third party in any such challenge (each, a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Challenge</u></font>&#8221;).


    If a Sublicensee brings any such Patent Challenge or assists a third party in bringing any such Patent Challenge (except as required under a court order or subpoena), then Licensor may send a written demand to Licensee to terminate such sublicense. If
    Licensee fails to so terminate such sublicense within thirty (30) days after Licensor&#8217;s demand, Licensor may terminate this Agreement. In any country(ies) where Licensor may not terminate this Agreement in the event of a Patent Challenge, if: (i)
    Licensee brings a Patent Challenge against Licensor; (ii) Licensee assists a third party in bringing a Patent Challenge against Licensor (except as required under a court order or subpoena); or (iii) a Sublicensee brings a Patent Challenge or assists a
    third party in bringing a Patent Challenge (except as required under a court order or subpoena), Licensor sends a written demand to Licensee to terminate such sublicense, and Licensee fails to so terminate such sublicense within thirty (30) days after
    Licensor&#8217;s demand, and such Patent Challenge is not successful (<font style="font-family: 'Times New Roman'; font-style: italic;">i.e., </font>the Licensed Patent(s) subject to such Patent Challenge retain Valid Claims), then the applicable percentage
    of Sublicense Fees payable under <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u> shall be doubled. In the event that such a Patent Challenge is successful, Licensee will have no right to recoup any payments made during the
    period of such Patent Challenge.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effects of Termination; Termination of License</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.5.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Upon termination or expiration of this
        Agreement for any reason, Licensee&#8217;s rights to the Licensed Patents and Licensed Know-How, inclusive of the Licensed Products, which have been granted hereunder and all use thereof will terminate. For the avoidance of doubt, any subcontracting
        agreement entered into by Licensee under <u><font style="font-family: 'Times New Roman';">Section 2.3</font></u> shall survive the termination or expiration of this Agreement unless the terms of such subcontracting agreement provide otherwise.
        Notwithstanding the foregoing, in event of expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement, Licensee and Licensor shall cooperate in Pursuing Opportunities that
        Licensee has Identified prior to the effective date of expiration of this Agreement for up to one (1) year from the effective date of expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for
        convenience) of this Agreement, and Licensee shall collect its applicable share of Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor under any such licenses entered into
        by Licensor with respect to such Identified Opportunities during such one (1) year period, provided that such Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor should be
        treated as Sublicense Fees hereunder and shared between Licensee and Licensor in accordance with <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u> and such license shall survive in accordance with <u><font style="font-family: 'Times New Roman';">Section 7.6</font></u> below (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>). Licensee&#8217;s right to Pursue the Opportunities pursuant to this <u><font style="font-family: 'Times New Roman';">Section 7.5.1</font></u> is expressly made subject to applicable provisions of this Agreement, including the covenants of Licensee set forth in <u><font style="font-family: 'Times New Roman';">Sections
            2.2</font></u>, and <u><font style="font-family: 'Times New Roman';">6.2</font></u>, which shall survive any expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement
        with respect to such Opportunities (and for clarity, Licensee&#8217;s foregoing right to Pursue the Opportunities shall terminate for Licensee&#8217;s material breach by of such surviving provisions). For clarity, if Licensee Pursues Opportunities beyond the
        effective date of expiration or termination pursuant to this <u><font style="font-family: 'Times New Roman';">Section 7.5.1</font></u>, Licensee will continue to pay the Patent Expenses as set forth in <u><font style="font-family: 'Times New Roman';">Section 8.2</font></u>.</font></font></div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.5.2</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';">During the Term, Licensee may, subject to
        Licensor&#8217;s prior written consent (such consent not to be unreasonably withheld), identify two (2) Opportunities, whether or not such Opportunities are Identified Opportunities, as &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Surviving


            Opportunities</u></font>&#8221;. Notwithstanding anything to the contrary, Licensee and Licensor shall cooperate in Pursuing the Surviving Opportunities for up to four (4) years from the effective date of expiration or termination (unless this
        Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement, and Licensee shall collect its applicable share of Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>)
        received by Licensor under any such licenses entered into with respect to such Surviving Opportunities that are Identified during such four (4) year period, provided that such Sublicense Fees (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>) received by Licensor should be treated as Sublicense Fees hereunder and shared between Licensee and Licensor in accordance with <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u>
        and such license shall survive in accordance with <u><font style="font-family: 'Times New Roman';">Section 7.6</font></u> below (<font style="font-family: 'Times New Roman'; font-style: italic;">mutatis mutandis</font>). Licensee&#8217;s right to Pursue
        the Surviving Opportunities is expressly made subject to the applicable provisions of this Agreement, including the covenants of Licensee set forth in <u><font style="font-family: 'Times New Roman';">Sections 2.2</font></u> and <u><font style="font-family: 'Times New Roman';">6.2</font></u>, which shall survive any expiration or termination (unless this Agreement is terminated by Licensor for cause or by Licensee for convenience) of this Agreement with respect to such
        Surviving Opportunities (and for clarity, Licensee&#8217;s foregoing right to Pursue the Surviving Opportunities shall terminate for Licensee&#8217;s material breach of such surviving provisions). For clarity, if Licensee Pursues Opportunities beyond the
        effective date of expiration or termination pursuant to this <u><font style="font-family: 'Times New Roman';">Section 7.5.2</font></u>, Licensee will continue to pay the Patent Expenses as set forth in <u><font style="font-family: 'Times New Roman';">Section 8.2</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Effect on Sublicenses</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In the event that this </font><font style="font-size: 10pt;">Agreement


      <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">is terminated or expires</font> for any reason<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, and if </font>Licensee <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">requests that any given sublicense(s) survive such termination (each, a &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Surviving Sublicense</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;), such Surviving Sublicense(s) shall be considered a direct </font>license <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">from </font>Licensor <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">to such surviving Sublicensee, unless such Sublicensee is (a) an Affiliate of Licensee, (b) in material default of any provision of the applicable sublicense, or (c) the basis for
        termination of this Agreement is due to such Sublicensee&#8217;s actions or inactions ((a)-(c), an &#8220;</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Ineligible Sublicensee</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;)</font>; provided that such Sublicensee agrees in writing that (i) Licensor is entitled to enforce all relevant provisions directly against such Sublicensee, and (ii) Licensor shall not
      assume, and shall not be responsible to such Sublicensee for, any representations, warranties or obligations of Licensee to such Sublicensee, other than to permit such Sublicensee to exercise any rights to <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the </font>Licensed Patents or Licensed Know-How <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">sublicensed to such Sublicensee by </font>Licensee, to the extent consistent with the terms of this
      Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">. For clarity, in the event that this Agreement expires (but for clarity, not in the event that this Agreement is terminated for any reason), any Sublicense Fees (</font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);">mutatis mutandis</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">) received by Licensor pursuant to the Surviving Sublicenses should be
        treated as Sublicense Fees under this Agreement and shared between Licensee and Licensor in accordance with <u>Section </u></font><u><font style="font-family: 'Times New Roman';">5.1</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Accrued Obligations</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Expiration or termination of this Agreement will not release either Party from any obligation that matured prior to the effective date of such
    expiration or termination. Upon expiration or termination of this Agreement for any reason, any unpaid amounts payable to Licensor shall become immediately due, and payment thereof shall remain an ongoing obligation of Licensee until such amount is
    paid in full.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Survival</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Upon expiration or termination of this Agreement, <u><font style="font-family: 'Times New Roman';">Sections 1</font></u>, <u><font style="font-family: 'Times New Roman';">3.4</font></u>, <u><font style="font-family: 'Times New Roman';">5</font></u>, <u><font style="font-family: 'Times New Roman';">6.4</font></u>, <u><font style="font-family: 'Times New Roman';">6.5</font></u>, <u><font style="font-family: 'Times New Roman';">7.5</font></u>-<u><font style="font-family: 'Times New Roman';">7.8</font></u> (provided that, all applicable provisions of this Agreement, including <u><font style="font-family: 'Times New Roman';">Sections
        2.2</font></u> and <u><font style="font-family: 'Times New Roman';">4.1</font></u> shall survive to the extent applicable with respect to<u> <font style="font-family: 'Times New Roman';">Section 7.5</font></u>), <u><font style="font-family: 'Times New Roman';">8.1</font></u>, <u><font style="font-family: 'Times New Roman';">8.6</font></u>, <u><font style="font-family: 'Times New Roman';">8.7</font></u>, <u><font style="font-family: 'Times New Roman';">8.8</font></u>, and <font style="font-family: 'Times New Roman';"><u>9</u></font>-<font style="font-family: 'Times New Roman';"><u>11</u></font> will, with related definitions, survive and remain in full force and effect.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 8</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Intellectual Property Rights</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Rights in Improvements, Improvement Patents and Independent Inventions</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Subject to the rights granted to
        Licensee in <u><font style="font-family: 'Times New Roman';">Section 2.1</font></u> and <u><font style="font-family: 'Times New Roman';">Section 2.2</font></u>, Licensor shall own, and Licensee shall assign and hereby does assign (and shall
        ensure that all of its Sublicensees assigns), to Licensor all right, title and interest in and to all Improvements and Improvement Patents, including all related certificates of correction, reissue certificates, and supplementary protection
        certificates, and all other rights granted under 35 U.S.C. &#167; 307, 35 U.S.C. &#167; 318, 35 U.S.C. &#167; 328, and 35 U.S.C. &#167; 254-257. Licensee shall execute and assist (and ensure that its Sublicensees execute and assist) with any and all applications,
        assignments, or other instruments which Licensor deems necessary to perfect the foregoing assignment and/or to evidence, apply for, obtain, maintain, defend or enforce patent or other intellectual property protection in any and all countries
        worldwide with respect to Improvements assigned to Licensor as set forth above or to protect otherwise Licensor&#8217;s interest therein.<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>[*]</u></font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee shall own all right, title and
        interest in and to all Independent Inventions invented, developed, created, or reduced to practice by or on behalf of Licensee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.1.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Improvement Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>[*]</u><u>&#160;</u></font>shall be automatically included as part of the Licensed Patents. Licensee and Licensor agree promptly to update <u><font style="font-family: 'Times New Roman';">Schedule 1.21</font></u> of this Agreement attached hereto upon written request by either Party from time to time, to reflect the inclusion of such Improvement Patents in the Licensed Patents. Each Party will use reasonable efforts to
        disclose to the other Party during the Term any and all Improvements and Improvement Patents.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Patent Prosecution</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the Term, as between the Parties, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensor </font>will be responsible for
    preparing, filing, prosecuting and maintaining all patent applications and patents included in the Licensed Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">in the Territory. </font>For the sake of clarity, as used herein
    the term &#8220;prosecution&#8221; shall include interference, opposition, and derivation proceedings, <font style="font-family: 'Times New Roman'; font-style: italic;">ex parte</font> reexaminations, <font style="font-family: 'Times New Roman'; font-style: italic;">inter partes</font> reviews, post-grant reviews, and appeals of each of the foregoing (and any foreign equivalents) in connection with the Licensed Patents. Licensor, with Licensee&#8217;s consent not to be unreasonably withheld, conditioned, or
    delayed, shall select patent counsel to conduct such activities regarding the Licensed Patents. Licensor shall keep Licensee informed of prosecution activities for Licensed Patents<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>providing


    Licensee an opportunity to provide comments. Licensor shall cause all patent applications and patents included in the Licensed Patents <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">in the Territory</font> to be diligently
    prosecuted. Licensee, in its sole discretion, may elect to irrevocably discontinue paying for prosecution and maintenance of all patents and patent applications included in the Licensed Patents in any jurisdiction (i.e., region or country), in which
    case, Licensee shall provide Licensor notice thereof in accordance with <font style="font-family: 'Times New Roman';"><u>Section 8.3</u></font> and (i) all patents and patent applications in such jurisdiction (including any Improvement Patents in such
    jurisdiction) will no longer be deemed Licensed Patents hereunder, (ii) Licensee will no longer be responsible for the Patent Expenses related thereto, (iii) all licenses and other rights granted to Licensee and its Wholly-Owned Subsidiaries under this
    Agreement with respect to such jurisdiction will terminate, and (iv) such jurisdiction will be excluded from the Territory. Except as set forth in the previous sentence, all Patent Expenses will be borne by Licensee, including such Patent Expenses that
    reasonably were incurred prior to the A&amp;R Effective Date. At Licensor&#8217;s request, Licensee shall enter into third-party payer agreements with Licensor&#8217;s patent counsel.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Notification to
          Licensor.</u></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In the event that <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> decides to irrevocably discontinue paying for
    prosecution and maintenance of all patent applications and patents included in the Licensed Patents in any jurisdiction pursuant to <u><font style="font-family: 'Times New Roman';">Section 8.2</font></u>, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Licensee</font> will notify Licensor thereof within such time as may be reasonably necessary for Licensor to continue such prosecution and/or maintenance at its own expense (but in no event less than ninety (90) days), and
    Licensor will <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">have the right, but not the obligation, to so continue such prosecution and/or maintenance at its own cost and expense.</font></div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
    </font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Enforcement of Licensed Patents</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Notice</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If either Party becomes aware of any infringement in the Field, anywhere in the Territory, of any issued patent within the Licensed Patents, such Party
    will notify the other Party in writing within thirty (30) days to that effect.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Infringement of Licensed Patents by Third Parties</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Subject at all times to the rights
        granted by Licensor under the Existing License Agreements, in the case of any infringement of any Licensed Patent in the Field by any third party, Licensee will have the first right, but not the obligation, to cause such third party to cease
        infringement and to otherwise enforce such Licensed Patent or to defend the Licensed Patent in any declaratory judgment action brought by third party(ies) which alleges the invalidity, unenforceability or non-infringement of the rights associated
        with the Licensed Patent. Before commencing any such enforcement action, Licensee shall consult in good faith with Licensor. Licensee shall not compromise or settle any such enforcement action in a way that (i) could reasonably be expected to
        affect the validity or enforceability of any Licensed Patents, (ii) change the scope of the claims of any Licensed Patents, or (iii) result in an admission of liability on the part of Licensor, in each case, without Licensor&#8217;s prior written
        consent. All costs and expenses associated with enforcing the Licensed Patent in any such action will be borne by Licensee. Licensor will, at Licensee&#8217;s cost and expense, cooperate and provide reasonable assistance in any action described in this <u><font style="font-family: 'Times New Roman';">Section 8.4.2.1</font></u>. Except for providing such cooperation and reasonable assistance, Licensor will have no obligation regarding the legal actions described herein; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided that</u></font> if required to enable Licensee to initiate or continue such action, Licensor will join such action at Licensee&#8217;s request and expense, or allow where required by law for Licensee
        to proceed in Licensee&#8217;s name. Any recovery or compensation resulting from such proceeding will first be used to reimburse Licensor for any unreimbursed expenses incurred in connection with providing assistance or joining the proceeding at
        Licensee&#8217;s request, and thereafter to reimburse Licensee for any other unreimbursed expenses incurred in connection with the proceeding (including attorneys&#8217; fees, expert witness fees, court fees, and related charges), and the remainder, if any,
        will be considered Sublicense Fees and shared between Licensee and Licensor in accordance with <u><font style="font-family: 'Times New Roman';">Section 5.1</font></u>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.4.2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">If Licensee does not, within a
        reasonable period after becoming aware of a third party infringement of the Licensed Patents in the Field, but in any event no less than ninety (90) calendar days from becoming aware of the third party infringement, (i) initiate legal proceedings
        against such threatened or actual infringement, or defend legal proceedings brought by a third party, as provided in <u><font style="font-family: 'Times New Roman';">Section 8.4.2.1</font></u> above, or (ii) take other reasonable steps to cause
        such infringement to terminate (for example, by initiating licensing discussions), Licensor may deliver written notice to Licensee that it intends to take action to cause such infringement to terminate, and subject to consultation with Licensee,
        Licensor may take such action as it deems reasonably necessary to enforce its rights in the Licensed Patents in the Field, including, to bring, at its own expense, an infringement action or file any other appropriate action or claim related to such
        infringement against any third party, provided that Licensor shall not compromise or settle any such enforcement action in a way that (i) could reasonably be expected to affect the validity or enforceability of any Licensed Patents, (ii) change the
        scope of the claims of any Licensed Patents, or (iii) result in an admission of liability on the part of Licensee, in each case, without Licensee&#8217;s prior written consent. All costs and expenses associated with enforcing the Licensed Patent in any
        such action will be borne by Licensor. Licensee will, at the reasonable request of Licensor, cooperate and provide reasonable assistance in any action taken by Licensor and described in this <u><font style="font-family: 'Times New Roman';">Section
            8.4.2.2</font></u> and, if required to enable Licensor to initiate or continue such action, will join such action at Licensor&#8217;s reasonable request, all at Licensor&#8217;s cost and expense. Any recovery or compensation resulting from such proceeding
        undertaken by Licensor will first be used to reimburse Licensee for any unreimbursed expenses in connection with providing assistance or joining the proceeding at Licensor&#8217;s request, and thereafter to reimburse Licensor for any other unreimbursed
        expenses incurred in connection with the proceeding (including attorneys&#8217; fees, expert witness fees, court fees, and related charges), and the remainder, if any, will be retained solely by Licensor.</font></font></div>
  <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Infringement of Third-Party Rights</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.5.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Each Party will promptly notify the
        other Party in writing of any notice or claim of any allegation of infringement or commencement against it of any suit or action for infringement of a third-party patent based upon or arising from actions taken under the licenses granted in this
        Agreement (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Third-Party Infringement Claim</u></font>&#8221;). If such Third-Party Infringement Claim is alleged or commenced against Licensee, Licensee will have the sole right to
        defend and settle such Third-Party Infringement Claim, and Licensee will not be obligated to enter into negotiations with such third party to obtain rights for either Licensee or Licensor under the third-party patent. Subject to, and without
        limiting <u><font style="font-family: 'Times New Roman';">Section 9.1</font></u>, if such Third-Party Infringement Claim is alleged or commenced against Licensor, Licensor will have the first right, but not the obligation, to defend and settle
        such Third-Party Infringement Claim,<font style="font-family: 'Times New Roman'; color: rgb(255, 0, 0);">&#160;</font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that Licensor will not be obligated
        to enter into negotiations with such third party to obtain rights for Licensee under the third-party patent. With respect to any such defense by Licensee of a Third-Party Infringement Claim alleged or commenced against Licensee, Licensee will not
        make any settlements of such Third-Party Infringement Claim that would materially adversely affect Licensor&#8217;s rights or interests in the Licensed Patents without first obtaining Licensor&#8217;s prior written consent, not to be unreasonably withheld,
        conditioned, or delayed. With respect to any such defense by Licensor of a Third-Party Infringement Claim alleged or commenced against Licensor, Licensor will not make any settlements of such Third-Party Infringement Claim that would materially
        adversely affect Licensee&#8217;s rights or interests in the Licensed Patents without first obtaining Licensee&#8217;s prior written consent, not to be unreasonably withheld, conditioned, or delayed. In any defense of a Third-Party Infringement Claim under
        this <u><font style="font-family: 'Times New Roman';">Section 8.5</font></u>, the non-defending Party will reasonably cooperate with the defending Party in the defense of such Third-Party Infringement Claim, including by cooperating with the
        defending Party in the assessment of such Third-Party Infringement Claim and, if requested by the defending Party, by assisting such defending Party in the development and evaluation of any available defense(s) in response to such Third-Party
        Infringement Claim based on the invalidity and/or non-infringement of the subject third-party patent(s). Subject to, and without limiting <u><font style="font-family: 'Times New Roman';">Section 9.1</font></u>, the non-defending Party shall bear
        the cost of its cooperation in any such defense of a Third-Party Infringement Claim. Additionally, if in Licensee&#8217;s reasonable opinion, a Licensed Product is likely to become the subject of a Third-Party Infringement Claim, upon Licensee&#8217;s
        reasonable request therefor, Licensor shall in good faith assist Licensee in the assessment of the subject third-party patent(s) and the development of any bases of invalidity and/or non-infringement of such third-party patent(s), subject to
        Licensee&#8217;s reimbursement of any costs and expenses incurred by Licensor in connection therewith.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidential Information</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Party shall maintain the Confidential Information of the other Party in strict confidence, and will not disclose, divulge or otherwise communicate
    such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement, or with the express written consent of the Party who provided such Confidential Information.
    Each Party will maintain the confidentiality of the other Party&#8217;s confidential information using methods and practices that are substantially similar to those that the receiving Party uses to maintain the confidentiality of its own confidential
    information, but in no event less than a reasonable degree of care. Except as may be authorized in advance in writing by the disclosing Party, the receiving Party will only grant access to the Confidential Information to its employees and agents as
    necessary to carry out activities under this Agreement and such employees and agents will have entered into non-disclosure agreements consistent with the terms of this <u><font style="font-family: 'Times New Roman';">Section 8.6</font></u>. The
    obligations of confidentiality described above will not pertain to that part of any Confidential Information to the extent that it is supported by competent written proof that:</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">such information was lawfully in the
        receiving Party&#8217;s possession or control prior to the time it received the information from the disclosing Party;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">such information was developed by the
        receiving Party independently of and without reference to the Confidential Information of the disclosing Party;</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.3</font><font style="font-size: 10pt;">&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">such information was, at the time it
        was disclosed to or obtained by the receiving Party, or thereafter became, available to the public through no act or omission of the Party holding such information; or</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">such information was lawfully obtained
        by the receiving Party from a third party that has the right to disclose such information free of any obligations of confidentiality.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In addition, a receiving Party may
        disclose such Confidential Information to the limited extent required to do so by Applicable Law or a proper legal, governmental or other competent authority, or by the rules of any securities exchange on which any security issued by either Party
        is traded, or included in any filing or action taken by the receiving Party to obtain or maintain government clearance or approval to market a subject Licensed Product. Except where impracticable, such required Party shall give the other Party
        reasonable advance notice of such disclosure requirement and shall afford the other Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required disclosure, or, where it is impracticable to give an advance
        notice, such required Party shall give the other Party reasonable notice promptly after such required disclosure. In the event of any such required disclosure, the required Party shall disclose only that portion of the Confidential Information
        legally required to be disclosed.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.6.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In addition, either Party may disclose Confidential Information, including this </font>Agreement, <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and the terms hereof (</font>including <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">providing a copy hereof, redacted as appropriate) to any bona fide potential licensor, licensee, partner or permitted Sublicensee </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">successor to said </font>Party<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8217;s interest under this </font>Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, to a bona
          fide potential lender from which said Party is considering borrowing money, to a bona fide potential collaborator in connection with development </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">commercialization of </font>Licensed


        Products<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, to any bona fide financial investor from which said Party may take money, to any insurance broker, business, financial or scientific consultants, attorneys, and
          accountants; </font><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>provided, however</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, in any such case said Party shall
          first obtain a written obligation of confidentiality no less stringent than that imposed in this </font><u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section </font><font style="font-family: 'Times New Roman';">8.6</font></u>
        (or in the case of attorneys or other professionals, an equivalent professional duty of confidentiality) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">from the bona fide potential licensor, licensee, partner, permitted
          Sublicensee </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">successor, bona fide potential lender, bona fide potential collaborator, bona fide financial investor, insurance broker, business, financial or scientific
          consultant, attorney or accountant.</font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Use of Names</u>.</font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Neither Party may identify the other Party in any promotional advertising or other promotional materials to be disseminated to the public or any portion
    thereof, or use the name of any staff member or employee of the other Party or any trademark, service mark, trade name, symbol or logo that is associated with the other Party, without the other Party&#8217;s prior written consent. Notwithstanding the
    foregoing, and for the avoidance of doubt, without the consent of the other Party either Party may comply with disclosure requirements of all Applicable Laws relating to its business, including United States and state securities laws. Each Party may
    include the other Party&#8217;s name, logo, and a brief description of such other Party on said Party&#8217;s website.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Press Releases</u>.</font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Parties shall mutually agree upon the timing and content of any press releases or other public announcement relating to this Agreement and the
    transactions contemplated herein, provided, however, that either Party or its Affiliates may disclose the relevant terms of this Agreement to the extent required to comply with the rules and regulations promulgated by the U.S. Securities and Exchange
    Commission or any equivalent governmental agency or Applicable Law in any country in the Territory, provided that such Party shall use reasonable efforts to redact sensitive information and shall submit a confidential treatment request in connection
    therewith, after consultation with the other Party.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 9</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Indemnification; Insurance</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Indemnification by Licensee</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.1.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee will indemnify, defend and hold
        harmless Licensor, its Affiliates and their respective directors, officers, employees, consultants, Licensor and agents, and their respective successors, heirs, and assigns (each a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensor


            Indemnitee</u></font>&#8221;), against all third party suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and reasonable attorneys&#8217; fees), including claims
        resulting from or connected to the death of or injury to any person or persons, or any damage to property, resulting from, arising out of, or otherwise attributable to Licensee&#8217;s or, as applicable Licensee&#8217;s Affiliate&#8217;s or Sublicensee&#8217;s: (a)
        negligence or misconduct in connection with this Agreement (and for clarity, not with respect to the provision of services contemplated under <u><font style="font-family: 'Times New Roman';">Section 3.1</font></u> which shall be governed by the
        terms of a separate services agreement between Licensee and the applicable Sublicensee), (b) failure to materially comply with Applicable Laws or the terms of this Agreement, including any material breach of Licensee&#8217;s express representations and
        warranties set forth in this Agreement, or (c) Exploitation of Licensed Products or the exercise of the licenses granted under this Agreement, including the sublicensing, production, manufacture, sale, use, lease, consumption, administration,
        shipping, storage, transfer, advertisement of the Licensed Patents, Licensed Know-How or Licensed Products, or any activity arising from or in connection with any right or obligation of Licensee hereunder, except in each case to the extent
        resulting from, arising out of, or otherwise attributable to Licensor&#8217;s failure to comply with Applicable Laws or the terms of this Agreement, including any breach of any express representation, warranty or covenant set forth in this Agreement, or
        any act of gross negligence or intentional misconduct by Licensor Indemnitee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.1.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Licensor will promptly give notice to
        Licensee of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might be covered by this <u><font style="font-family: 'Times New Roman';">Section 9.1</font></u> and Licensee will have the right to
        defend the same, including selection of counsel and control of the proceedings; provided that Licensee will not, without the written consent of the applicable Licensor, settle or consent to the entry of any judgment with respect to any such third
        party claim (x) that does not release the applicable Licensor Indemnitee(s) from all liability with respect to such third party claim or (y) which may materially adversely affect Licensor or the Licensor Indemnitees or under which such Licensor or
        the applicable Licensor Indemnitee(s) would incur any obligation or liability, other than one as to which Licensee has an indemnity obligation hereunder. Licensor agrees to fully cooperate and aid such defense. Licensor at all times reserve the
        right to select and retain counsel of its own at its own expense to defend such Licensor&#8217;s interests.</font></font></div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"> <br>
      </font></font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Indemnification by Licensor</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.2.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensor will indemnify, defend and hold
        harmless Licensee, its Affiliates and their respective directors, officers, employees, consultants, Licensor and agents, and their respective successors, and assigns (each a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Licensee


            Indemnitee</u></font>&#8221;), against all third party suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses (including legal expenses, investigative expenses, and reasonable attorneys&#8217; fees) resulting from, arising
        out of, or otherwise attributable to Licensor&#8217;s (a) negligence or misconduct in connection with this Agreement (and for clarity, not with respect to the provision of services contemplated under <u><font style="font-family: 'Times New Roman';">Section


            3.1</font></u> which shall be governed by the terms of a separate services agreement between Licensor and the applicable Sublicensee<font style="font-family: 'Times New Roman';"><u>)</u></font>, or (b) failure to materially comply with
        Applicable Laws or the terms of this Agreement, including any material breach of Licensee&#8217;s express representations and warranties set forth in this Agreement, except to the extent resulting from, arising out of, or otherwise attributable to
        Licensee&#8217;s failure to comply with Applicable Laws or the terms of this Agreement, including any breach of any express representation, warranty or covenant set forth in this Agreement, or any act of gross negligence or intentional misconduct by a
        Licensee Indemnitee.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.2.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Licensee will promptly give notice to
        Licensor of any suits, actions, claims, proceedings, liabilities, demands, damages, losses, or expenses which might be covered by this <u><font style="font-family: 'Times New Roman';">Section 9.2</font></u> and Licensor will have the right to
        defend the same, including selection of counsel and control of the proceedings; provided that Licensor will not, without the written consent of Licensee, settle or consent to the entry of any judgment with respect to any such third party claim (x)
        that does not release the Licensee Indemnitee(s) from all liability with respect to such third party claim or (y) which may materially adversely affect Licensee or the Licensee Indemnitee or under which Licensee or the Licensee Indemnitee would
        incur any obligation or liability, other than one as to which Licensor has an indemnity obligation hereunder. Licensee agrees to fully cooperate and aid such defense. Licensee at all times reserves the right to select and retain counsel of its own
        at its own expense to defend Licensee&#8217;s interests.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Insurance.</u></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Both Parties <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall maintain in full force and effect during the </font>Term <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and for a </font>period of three (3) years <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">after expiration </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">termination of this </font>Agreement<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, worker&#8217;s compensation, general liability and professional liability, clinical trial liability, and product liability
      insurance coverage, all in such amounts and with such scope of coverages as are reasonably sufficient to </font>cover its respective <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">obligations under this </font>Agreement <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(</font>including <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the indemnity obligations set forth in </font><u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section </font><font style="font-family: 'Times New Roman';">9.1</font></u> and<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section
      </font><font style="font-family: 'Times New Roman';">9.2</font></u>) <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and as are customary in the life sciences and pharmaceutical industries. Upon written request of a Party, the
      other Party, shall provide evidence of such insurance to the requesting Party. </font>Each Party <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall be named as an additional insured with respect to such insurance policies held
      by the other Party, and </font>each Party <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">shall ensure that the other Party</font>&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">will receive no less than
      fourteen (14) days&#8217; prior notice of any cancelation, non-renewal </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">material change in such insurance coverage.</font></div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br>
    </font></div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 10</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Alternative Dispute Resolution</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Negotiation</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;">In the event of any dispute or disagreement between Licensor and Licensee as to the interpretation of any provision of this Agreement or any other
    related document (or the performance of any obligations hereunder or thereunder), the matter, upon written request of either Licensor or Licensee, shall be referred to representatives of Licensor and Licensee for decision, each such Party being
    represented by an Executive Officer (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Representatives</u></font>&#8221;). The Representatives shall promptly meet and use good faith efforts to resolve the dispute. If the
    Representatives do not mutually agree upon a decision within thirty (30) calendar days (as extended by the last sentence of this <u><font style="font-family: 'Times New Roman';">Section 10.1</font></u>) after reference of the matter to them, the
    Parties shall submit to mediation by a single independent mediator, with expertise and experience applicable to the subject matter of the dispute, mutually agreeable to the Parties and in accordance with procedures as may be mutually agreed in writing
    by the Parties. If the dispute is not resolved pursuant to such mediation (including if the Parties are unable to mutually agree on the selection of a mediator or the relevant procedures for such mediation), then each of the Licensor and Licensee shall
    be free to exercise the remedies available to it under <u><font style="font-family: 'Times New Roman';">Section 10.2</font></u>. Each of the Licensor and Licensee may extend the period of time for negotiation among the Representatives for an
    additional period of thirty (30) calendar days on one (1) occasion per dispute.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Submission to Arbitration</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If the Licensor and Licensee are unable to resolve such dispute pursuant to <u><font style="font-family: 'Times New Roman';">Section 10.1</font></u>,
    the dispute shall be submitted to binding arbitration (without any recourse to the federal or state courts except to enforce any arbitral award or, within forty five (45) days of an Arbitrator&#8217;s rendering of a final decision, to appeal such final
    decision based solely on a claim that the Arbitrator engaged in gross misconduct or made a material error or miscalculation in his or her decision) in accordance with the rules of JAMS (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>JAMS</u></font>&#8221;)


    then in force (except as expressly modified below), and the arbitration hearings shall be held before a single arbitrator (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Arbitrator</u></font>&#8221;) in New York, New York. The Licensor
    and Licensee agree to appoint an Arbitrator who is knowledgeable in the biotechnology and/or life sciences industries. If the Licensor and Licensee cannot agree upon an Arbitrator within ten (10) days after a demand for arbitration has been filed with
    the JAMS by either of them, either or both of the participating Licensor and Licensee may request the JAMS to name a panel of five (5) candidates to serve as Arbitrator. The participating Licensor and Licensee shall each, in successive rounds (with the
    Party demanding the arbitration having the first chance to strike a name), strike one name off this list until only one name remains, and such last-named person shall be the Arbitrator. In the event that the dispute involves a claim of more than
    $5,000,000, then instead of one Arbitrator, there shall be three (3) Arbitrators who are knowledgeable in the biotechnology and/or life sciences industries, with each Party selecting one (1) Arbitrator and the two (2) Arbitrators so chosen, shall
    select a third arbitrator, who shall serve as the chair of the arbitration panel.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Conduct of Arbitration</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Arbitrator shall be required to (a) follow the substantive rules of New York State or Federal law, as applicable, (b) have all testimony be
    transcribed, and (c) accompany his or her award with findings of fact and a statement of reasons for the decision. The Arbitrator(s) shall have the authority to permit discovery for no more than thirty (30) days, to the extent deemed appropriate by the
    Arbitrator(s), upon reasonable request of a participating Party. The Arbitrator(s) shall have no power or authority to (i) add to or detract from the written agreement of the Parties set forth herein, (ii) modify or disregard any provision of this
    Agreement or any of the other related documents, or (iii) address or resolve any issue not submitted by the Parties. The Arbitrator(s) shall hold proceedings during a period of no longer than thirty (30) calendar days promptly following conclusion of
    discovery, and the Arbitrator(s) shall render a final decision within thirty (30) days following conclusion of the hearings. The Arbitrator(s) shall have the power to grant injunctive relief (without the necessity of a Party posting a bond) in the
    event a Party has violated the confidentiality provisions set forth in this Agreement, but shall have no power to award punitive and/or exemplary damages in the event of a breach. In the event of any conflict between the commercial arbitration rules
    then in effect and the provisions of this Agreement, the provisions of this Agreement shall prevail and be controlling.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Interim Relief</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Either Licensor or Licensee may, without waiving any remedy under this Agreement, apply to the Arbitrator(s) for interim injunctive relief until the
    arbitration award is rendered or the controversy is otherwise resolved. Either Licensor or Licensee also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to
    protect the rights regarding the Intellectual Property or Confidential Information of that Party pending the arbitration award. The Arbitrator(s) shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s
    compensatory damages.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Cost of Arbitration</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Licensor and Licensee shall share in the actual and direct costs of the engagement of the Arbitrator, but the prevailing Party(ies) in the
    arbitration shall be reimbursed by the non-prevailing Party(ies) for the prevailing Party&#8217;s fees and costs of arbitration (e.g., the costs, fees and expenses of outside experts and counsel retained by the prevailing Party). If Licensor or Licensee is
    not deemed by the Arbitrator to be the primary prevailing Party, then each Party will pay its own costs, fees and expenses (including attorneys&#8217; fees) and an equal share of the Arbitrator(s)&#8217; fees and any administrative fees of arbitration.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Excluded Claims</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Unless otherwise mutually agreed upon by the Parties in writing, any Excluded Claims may be brought in the federal court located in the Southern
    District of New York, if federal jurisdiction is available, or, alternatively, in the state courts in New York, New York. Each of the Parties hereby submits to the jurisdiction of such courts for the purpose of any such litigation; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner
    provided by law. Each Party irrevocably and unconditionally agrees not to assert (a) any objection which it may ever have to the laying of venue of any such litigation in such courts, (b) any claim that any such litigation brought in any such court has
    been brought in an inconvenient forum, and (c) any claim that such court does not have jurisdiction with respect to such litigation. As used in this <u><font style="font-family: 'Times New Roman';">Section 10.6</font></u>, the term &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Excluded Claim</u></font>&#8221; means a dispute, controversy or claim that concerns: (x) the scope, construction, validity or infringement of a patent, trademark or copyright; or (y) any
    antitrust, anti-monopoly or competition law or regulation, whether or not statutory; or (z) Licensee&#8217;s or, as applicable, Licensee&#8217;s Affiliates or Sublicensee(s), Exploitation of Licensed Products or use of the Licensed Patents or Licensed Know-How
    outside of the Field.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Injunctive Relief; Specific Performance</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding anything to the contrary herein, nothing in this <font style="font-family: 'Times New Roman';">Section 10</font> shall preclude a Party
    from seeking injunctive relief or specific performance in a court of competent jurisdiction or through arbitration.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Confidentiality</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an Arbitrator may disclose the existence, content,
    or results of the arbitration without the prior written consent of the other Parties, except to its directors and officers, subject to the exceptions for other Confidential Information as set forth in <u><font style="font-family: 'Times New Roman';">Section


        8.6</font></u><font style="font-family: 'Times New Roman';"><u>.5</u></font> and <u><font style="font-family: 'Times New Roman';">Section 8.6.6</font></u>.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">10.9.&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>Statute of Limitations</u></font>.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or
    claim would be barred by the applicable New York State statute of limitations.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Section 11</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><u>Miscellaneous</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Compliance with Law</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with performing its obligations or exercising its rights under this Agreement, each Party agrees to comply with all Applicable Laws.
    Without limiting the foregoing, by entering into this Agreement, the Parties specifically intend to comply with, and require its Sublicensees complies with, all Applicable Laws, including, if applicable, such laws pertaining to Licensed Products,
    including (i) the federal anti-kickback statute (42 U.S.C. &#167;1320a-7b) and the related safe harbor regulations; and (ii) the Limitation on Certain Physician Referrals, also referred to as the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;">Stark Law</font>&#8221; (42 U.S.C. &#167;1395nn). Accordingly, no part of any consideration paid hereunder is a prohibited payment for the recommending or arranging for the referral of business or the ordering of items or services; nor are the payments
    intended to induce illegal referrals of business.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Assignment</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement will be binding upon and will inure to the benefit of each Party and each Party&#8217;s respective transferees, successors and assigns,
    pursuant to the provisions set forth below. Neither Party may transfer or assign this Agreement (i) without the prior written consent of the other Party, provided that if such transfer or assignment is to an Affiliate of such Party, such consent shall
    not be unreasonably withheld, conditioned or delayed, or (ii) as otherwise provided in this <u><font style="font-family: 'Times New Roman';">Section 11.2</font></u>. In the event that a third party (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Acquiring Party</u></font>&#8221;) acquires all or substantially all of a Party&#8217;s business, capital stock or assets, whether by sale, merger, change of control, operation of law or otherwise (an &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Acquisition</u></font>&#8221;), the rights granted to such Party under this Agreement shall inure to the benefit of the Acquiring Party. For the avoidance of doubt, in the event of an Acquisition, the Acquiring Party will be
    responsible for all payments and other obligations set forth in this Agreement, including, but not limited to, all payments set forth herein, and any obligations that matured prior to the Acquisition date. Upon an Acquisition, and payment thereof shall
    remain an ongoing obligation of the Acquiring Party until such amount is paid in full. Any attempted assignment in contravention of this <u><font style="font-family: 'Times New Roman';">Section 11.2</font></u> will be null and void.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Entire Agreement</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement constitutes the entire agreement between the Parties hereto with respect to the subject matter thereof and supersedes all previous
    negotiations, commitments, and writings with respect to such subject matter. For clarity, Licensor and Licensee, on behalf of itself and their respective Affiliates, each acknowledge and agree that the Exclusive License Agreement, by and among
    Licensor, Eterna Therapeutics LLC (f/k/a Brooklyn Immunotherapeutics LLC) (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Brooklyn</u></font>&#8221;) and Novellus Therapeutics Limited (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Novellus</u></font>&#8221;), as of April 26, 2021, as amended by that certain First Amendment to Exclusive License Agreement, by and among Licensor, Licensee, Brooklyn and Novellus, dated as of November 22, 2022 (as amended, the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Prior Agreement</u></font>&#8221;) (including Section 2A of the Prior Agreement) has been terminated under the Original Agreement, subject to applicable provisions in the Prior Agreement
    surviving as specified therein, provided that notwithstanding anything to the contrary herein or in the Prior Agreement, Licensor and Licensee, on behalf of itself and their respective Affiliates, hereby agree that Section 2A.10.4 of the Prior
    Agreement is terminated, and hereby superseded and replaced in its entirety by the applicable terms of this Agreement. The Parties hereby acknowledge and agree that the Prior Agreement, and all rights, obligations and licenses of each of the Parties
    under the Prior Agreement, shall be deemed to be superseded in all respects as of the Original Effective Date by this Agreement; provided that any dispute or alleged breach by a Party of any of the terms of the Prior Agreement during the period that
    the Prior Agreement was in effect shall be governed solely by the terms of the Prior Agreement and the terms and conditions of the Prior Agreement shall survive solely for the limited purpose set forth in this <u><font style="font-family: 'Times New Roman';">Section 11.3</font></u>. <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither </font>Party shall <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">be obligated by any undertaking </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">representation regarding that subject matter other than those expressly stated herein </font>or <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">as may be subsequently
      agreed to by the Parties hereto in writing.</font> In the event of any conflict or inconsistency between any provision of any Exhibit hereto and any provision of this Agreement, the provisions of this Agreement shall prevail.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Amendment</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly
    authorized officer of each Party.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Notices</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any notice required to be given pursuant to the provisions of this Agreement will be in writing and will be deemed to have been given at the time when
    actually received as a consequence of any effective method of delivery, including but not limited to hand delivery, or electronic transmission, including PDF (portable document format), delivery by a professional courier service or delivery by first
    class, certified or registered mail (postage prepaid) addressed to the Party for whom intended at the address below, or at such changed address as the Party will have specified by written notice in accordance with this <u><font style="font-family: 'Times New Roman';">Section 11.5</font></u>; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided, however</u></font>, that any notice of change of address will be effective only upon actual receipt.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If to </font><font style="font-size: 10pt;">Licensor<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">:</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Factor Bioscience Limited</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">c/o Factor Bioscience Inc.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Attn: </font><font style="font-size: 10pt;">Christopher


      Rohde, Ph.D., Chief Technology Officer</font></div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 17B</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cambridge, MA 02141</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">chris.rohde@factorbio.com</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With copy to which shall not constitute notice:</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Morgan, Lewis &amp; Bockius LLP</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Stephen L. Altieri, Ph.D., J.D.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">One Federal Street</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Boston, MA 02110-1726</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">stephen.altieri@morganlewis.com</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If to Licensee:</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Eterna Therapeutics, Inc.</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Sandra Gurrola, VP, Finance</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 18A</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cambridge MA 02141</div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">sandra.gurrola@eternatx.com</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With copy to which shall not constitute notice:</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">919 Third Avenue</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">New York, NY 10022</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Attn: Cheryl Reicin</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">creicin@mintz.com</div>
  <div style="text-align: left; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Governing Law</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The substantive law governing this Agreement (which shall be applied in the arbitration) shall be, with respect to disputes involving general contract
    or trade secret matters, the internal laws of the state of New York, and with respect to matters involving patents, the United States Patent Act, as to copyright matters, the United States Copyright Act, and as to trademark matters, the United States
    Trademark Act, each as amended from time to time. Any award rendered by the Arbitrator(s) shall be final, conclusive and binding upon the Parties to this Agreement, and judgment thereon may be entered and enforced in any state or federal court of
    competent jurisdiction.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Descriptive Headings</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement has been prepared jointly by the Parties and shall not be strictly construed against either Party. Ambiguities, if any, in this Agreement
    shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. Licensee hereby acknowledges that Licensor owns and/or has in-licensed the Licensed Patents and Licensed Know-How, and the use
    of the term &#8220;license&#8221; hereunder with reference to the rights granted to Licensee is understood by the Parties to mean either a direct license of Licensor&#8217;s ownership interest in the subject Licensed Patent or Licensed Know-How or a sublicense of
    Licensor&#8217;s in-licensed interest in the subject Licensed Patent or Licensed Know-How, as applicable. The headings of each Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the
    meaning of the language contained in the particular Section. Except where the context otherwise requires, the use of any gender shall be applicable to all genders, and the word &#8220;or&#8221; is used in the inclusive sense (and/or). The term &#8220;including&#8221; as used
    herein means including, without limiting the generality of any description preceding such term.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Independent Contractors</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensor and Licensee are independent contractors under this Agreement. Nothing contained in this Agreement will be deemed to create an employment,
    agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party
    will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Severability</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The illegality or partial illegality of any provision of this Agreement will not affect the validity of the remainder of this Agreement, or any
    provision thereof, and the illegality or partial illegality of any provision of this Agreement will not affect the validity of this Agreement in any jurisdiction in which such determination of illegality or partial illegality has not been made, except
    in either case to the extent such illegality or partial illegality causes this Agreement to no longer contain all of the material provisions reasonably expected by the Parties to be contained therein. Moreover, in the event that a court of competent
    jurisdiction determines that any provision of this Agreement is illegal or partially illegal, then it is the intention of the Parties that such provision be modified to the minimum extent deemed necessary by such court to make such provision
    enforceable and to give effect to the original intention of the Parties.</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.10.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Waiver of Compliance</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The failure of either Party to comply with any obligation, covenant, agreement or condition under this Agreement may be waived by the Party entitled to
    the benefit thereof only by a written instrument signed by the Party on granting such waiver, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition will not operate as a waiver of, or
    estoppel with respect to, any subsequent or other failure. The failure of any Party to enforce at any time any of the provisions of this Agreement will in no way be construed to be a waiver of any such provision, nor in any way to affect the validity
    of this Agreement or any part thereof or the right of any Party thereafter to enforce each and every such provision. No waiver of any breach of such provisions will be held to be waiver of any other or subsequent breach.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.11.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Counterparts</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement may be executed by original or facsimile signature in any number of counterparts, each of which need not contain the signature of more
    than one Party but all such counterparts taken together will constitute one and the same agreement.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.12.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Authority</u></font>.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The persons signing on behalf of Licensor and Licensee hereby warrant and represent that they have authority to execute this Agreement on behalf of the
    Party for whom they have signed.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.13.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Non-Disparagement</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Licensee on behalf of itself, its Affiliates and Sublicensees hereby covenants and agrees that it shall not make, write or publish any statement,
    assertion or claim that disclaims, disparages, denies, questions or otherwise challenges or casts doubt upon the validity, enforceability, scope, construction or inventorship of any patent Controlled by Licensor (including, but not limited to, any
    pending or issued claim(s) within the Licensed Patents). The provisions set forth in this <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u> shall take effect on the Original Effective Date, shall not require any further
    consideration or performance of Licensor, and shall survive the expiration or termination of this Agreement for five (5) years from the date or expiration or termination of this Agreement. If any part of this <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u> shall be deemed illegal or unenforceable by a court of competent jurisdiction, that part shall be deemed automatically deleted (or modified to the minimum extent deemed necessary by such court to make such
    provision enforceable and to give effect to the original intention of the Parties pursuant to <u><font style="font-family: 'Times New Roman';">Section 11.9</font></u>), such deletion being made as narrowly as possible (and, if possible, only in said
    jurisdiction) to maintain, as much as possible, the intent of this <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u>, and the remainder of this <u><font style="font-family: 'Times New Roman';">Section 11.13</font></u> shall,
    with related definitions, remain in full force and effect.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.14.</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>Non-Solicitation</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;">During the Term, neither Licensor nor Licensee, without the prior written consent of the other Party, shall directly or indirectly solicit for
    employment any employee of the other Party or any of its Affiliates or subsidiaries, or any person who has terminated his or her employment with the other Party or any of its Affiliates or subsidiaries within the previous twelve (12)-month period prior
    to any purported solicitation; <font style="font-family: 'Times New Roman'; font-style: italic;"><u>provided</u></font><font style="font-family: 'Times New Roman';"><u>, </u></font><font style="font-family: 'Times New Roman'; font-style: italic;"><u>however</u>,</font>
    the foregoing will not prevent Licensor or Licensee from employing any such person who contacts such Party on his or her own initiative without any direct or indirect solicitation by or encouragement from the soliciting or hiring person. General
    advertising which is not directed at any specific employee of a Party will not be deemed solicitation, and hiring of employees of such Party which are solicited in this manner will not be a breach of this provision.</div>
  <div style="text-align: justify; text-indent: 35.8pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.15</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic; color: rgb(0, 0, 0);"><u>Force Majeure</u></font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Neither </font><font style="font-size: 10pt; font-family: 'Times New Roman';">Party </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">hereto shall be liable for failures and delays in performance due to strikes, lockouts, fires, acts of God </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">the public enemy, riots, incendiaries, interference by civil </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">military authorities, acts of domestic or international terrorism, endemic, pandemic, and the results related to such acts, compliance
      with the laws of various states/countries, </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">with the orders of any governmental
      authorities, delays in transit </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">delivery on the part of transportation companies,
      failures of communication facilities, </font><font style="font-size: 10pt; font-family: 'Times New Roman';">or </font><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">any failure of sources of material.
      Notwithstanding the foregoing, if a Party is prevented from fulfilling its obligations under this Agreement for more than one hundred fifty (150) days due to such foregoing reasons, the other Party shall be entitled to immediately terminate this
      Agreement upon written notice.</font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-style: italic;"><u>No Preferential Treatment, Fraudulent Conveyance, Insolvency</u></font>.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Parties have not entered into this
        Agreement to provide any preferential treatment under section 547 of title 11 of the United States Code, as amended (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Bankruptcy Code</u></font>&#8221;) or any other applicable
        insolvency law.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Neither the execution or delivery of this
        Agreement or the consummation of the transactions hereunder were entered into with the intent by the Parties to effectuate a transaction that may be avoided under section 548(a) of the Bankruptcy Code, the Uniform Fraudulent Transfer Act (the &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>UFTA</u></font>&#8221;), the Uniform Voidable Transactions Act (&#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>UVTA</u></font>&#8221;) or any other applicable insolvency
        law. The Parties received reasonably equivalent value in exchange for the obligations provided hereunder. The transactions contemplated hereunder are not subject to avoidance under section 548(a) of the Bankruptcy Code, the UFTA, or any applicable
        insolvency law.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">As of the A&amp;R Effective Date,
        Licensor does not intend to file for protection or seek relief under title 11 of the Bankruptcy Code or any similar federal or state law providing for the relief of debtors. Licensor is not now insolvent (as such term is defined in the Bankruptcy
        Code or any other Applicable Law relating to insolvency).</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.16.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Notwithstanding any other provision of
        this Agreement to the contrary, in the event that Licensor becomes a debtor under the Bankruptcy Code and rejects this Agreement pursuant to section 365 of the Bankruptcy Code (a &#8220;<font style="font-family: 'Times New Roman'; font-style: italic;"><u>Bankruptcy


            Rejection</u></font>&#8221;): (a) any and all of the licensee and Sublicensee rights of Licensee arising under or otherwise set forth in this Agreement, shall be deemed fully retained by and vested in Licensee as protected intellectual property
        rights under section 365(n)(1)(B) of the Bankruptcy Code and further shall be deemed to exist immediately before the commencement of the bankruptcy case in which such Licensor is the debtor; (b) Licensee shall have all of the rights afforded to
        non-debtor licensees and Sublicensees under section 365(n) of the Bankruptcy Code and all other Applicable Laws; and (c) to the extent any rights of Licensee under this Agreement that arise after the termination or expiration of this Agreement are
        determined by a bankruptcy court to not be &#8220;intellectual property rights&#8221; for purposes of section 365(n), all of such rights shall remain vested in and fully retained by Licensee after any Bankruptcy Rejection as though this Agreement were
        terminated or expired. Licensee shall under no circumstances be required to terminate this Agreement after a Bankruptcy Rejection in order to enjoy or acquire any of its rights under this Agreement, but retains the right to do so in accordance
        herewith.</font></font></div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Remainder of page intentionally left blank.</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Parties hereto have duly executed this Amended and Restated Exclusive License Agreement as of the A&amp;R Effective Date.</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Factor Bioscience Limited</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2f80a6f85abd4e71a168899118aa8d4f">

      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
          <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
        </td>
        <td style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 3%;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;"><br>
          </div>
        </td>
        <td rowspan="1" style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 25%;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;">/s/ Christopher Rohde</div>
        </td>
        <td rowspan="1" style="vertical-align: top; font-size: 10pt; width: 69%; padding-bottom: 2px;">&#160;</td>
      </tr>

  </table>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
        <td style="vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
        </td>
        <td style="width: 22%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Christopher Rohde, PhD</div>
        </td>
        <td style="width: 68%; vertical-align: top; font-size: 10pt;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
        <td style="vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
        </td>
        <td style="width: 22%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Director</div>
        </td>
        <td style="width: 68%; vertical-align: top; font-size: 10pt;">&#160;</td>
      </tr>

  </table>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Eterna Therapeutics Inc.</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zdccb036538d84a4f85f559c959273e8a">

      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
        </td>
        <td rowspan="1" style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 3%;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;"><br>
          </div>
        </td>
        <td rowspan="1" style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt; width: 25%;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-style: italic;">/s/ Sandra Gurrola</div>
        </td>
        <td style="width: 69%; vertical-align: top; font-size: 10pt;">&#160;</td>
      </tr>

  </table>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
        <td style="width: 7%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
        </td>
        <td style="width: 22%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Sandra Gurrola</div>
        </td>
        <td style="width: 68%; vertical-align: top; font-size: 10pt;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
        <td style="width: 7%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
        </td>
        <td style="width: 22%; vertical-align: top; font-size: 10pt;">
          <div style="text-align: left; font-family: 'Times New Roman';">Vice President, Finance</div>
        </td>
        <td style="width: 68%; vertical-align: top; font-size: 10pt;">&#160;</td>
      </tr>

  </table>
  <div style="text-align: left; text-indent: 18pt; font-size: 10pt;"><br>
  </div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="font-size: 10pt;">
    <hr noshade="noshade" align="center" style="height: 2px; width: 100%; color: #54301A; background-color: #54301A; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>erna-20231114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20231114" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20231114" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20231114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20231114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>erna-20231114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>erna-20231114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.9.1.5178 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20231114.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139644299086768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 14,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1035 Cambridge Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 18A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ef20014811_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20231114.xsd" xlink:type="simple"/>
    <context id="c20231114to20231114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20231114to20231114"
      id="Fact_70bd02734fa24dfeb0114008727e8e44">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20231114to20231114"
      id="Fact_98703841345b448eba9f48742151dfb6">0000748592</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20231114to20231114"
      id="Fact_35234d1cfb4245ebaad41647342de055">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20231114to20231114"
      id="Fact_65f8498b7a9b45c89ca42dc5344269aa">2023-11-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20231114to20231114"
      id="Fact_8db86f2708ef4b15ba52236765c5e44b">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20231114to20231114"
      id="Fact_aad2f94da6574b45be5c7a8cdebedeb5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20231114to20231114"
      id="Fact_18cfa38c8a6f4d68b89711e9f60a8037">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20231114to20231114"
      id="Fact_db830d05ff594ddf9fadb9a7f68e32b7">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20231114to20231114"
      id="Fact_01021a18288047c8bbe9ee0e4844106a">1035 Cambridge Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20231114to20231114"
      id="Fact_13f9dcc78756407983eb1b188f353316">Suite 18A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20231114to20231114"
      id="Fact_423c1acd174d49fbb5a320b38f292f7e">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20231114to20231114"
      id="Fact_3e1128eef6dd481188edf4d2285e20e9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20231114to20231114"
      id="Fact_8961b8ee0b094fba8bd1fa38317ce664">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20231114to20231114"
      id="Fact_fdb2b3bf18cd49dc8b504c62ea30a3f3">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20231114to20231114"
      id="Fact_87e56ece077a4346992fc6a4a4caf65c">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20231114to20231114"
      id="Fact_28cdec7e047d40b38d061a160c6c9305">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20231114to20231114"
      id="Fact_34c83f3ba81446f3b9d277f945393d85">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20231114to20231114"
      id="Fact_5fe0b17be813468598371a345c265fe6">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20231114to20231114"
      id="Fact_cc13e1c15eed453f98aea676626cc99a">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20231114to20231114"
      id="Fact_c9de3d16f8a44682abc58249bb292acc">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20231114to20231114"
      id="Fact_9c8ac18c648f43d98901644d4f0d138e">ERNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20231114to20231114"
      id="Fact_5ea83905592641ab8668a993634299af">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20231114to20231114"
      id="Fact_ca6e82bf085d4680998d7612b97c2528">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  )@G!7'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ "8)P5R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    (  F"<%=ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  )@G!7PRU!^.T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  )@G!7
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    (  F"<%<V0TCA8@0  #X1   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  )@G!7
MGZ ;\+$"  #B#   #0              @ &D#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    (  F"<%>7BKL<P    !,"   +              "  8 /  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    (  F"<%<<.&7J/P$  #P"   /
M      "  6D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  )@G!7)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  )@G!799!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20014811_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20014811_8k.htm">ef20014811_8k.htm</File>
    <File>erna-20231114.xsd</File>
    <File>erna-20231114_lab.xml</File>
    <File>erna-20231114_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20014811_8k.htm": {
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20231114",
   "dts": {
    "inline": {
     "local": [
      "ef20014811_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "erna-20231114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20231114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20231114_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20231114to20231114",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20014811_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231114to20231114",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20014811_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001140361-23-053659-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-053659-xbrl.zip
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MG5F(V G93]"W*@41AZ<7+@1:FZ6I2 9V=_;!;[CW'WZ;1)^PLV\_G!Q-<-I
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M4STZW^D1_)JR\_L;R<XH$)(/2FZ^!J$$BGE*-OV)B<%THUUW-,?3K4,?ZK,
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MF2F2'!=%YF@\Z6W6%QBFK*F">/[R/,6FGM;HMMSWYP4%O>DLXN.D 63&-([
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M"WS_U1%E7_[*L;#Y=2&^4[BV4O0I38@.W#EOWMD^/+G>%3)J#32W&L/U2L8
MPQEG8P<+T$%T#5&%#8(;S*Z$3L@5 DYJ<[;VX"0.QNQ'OYVGF=EL2 B!2^R"
MW'N+F"@EIT4"(Z!$A6!JN!!YLW8YO(*WKZPW5B3HQH<65/[F&?YJ"6?#*5YW
ME7)V'XK7^X)+..%>^4#[!$W '";BC$)1O+=W/&_IR L.BHH3:2O+*UA\<'+
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M_:]Z< ^3((XS\/2A 1-#&#<Z7%^K$(]GDSGQCM8C[X8]9I.+58B/>.* (4K
MH%5.,WHO>M9PTW4PW'3=4#MN'#Q-NE4_,959I'MQGJ/$M3DGJV5BLX!;05*5
M1^R2G"0O41AZN[BMO+',ZLTU2B*H%P49X\TT0E!^#,@L@CYZ;FQ;O?H:_%@3
M/QB<E6R[[\YLG\JAZ9LME3>R^L!YFGZ)1B_&T0)FYKSE?Z<^KI9= 'L5@G X
M-!Q9QW+3.(S;J0AMO[[.,0A3IL[B,E')M7Z&T)N)T^<'HV,>QS@49Z@L.:V!
M'XF\P6KD2!A(80G2RS7I?9RB,EJM%@NICDASU,B#K^/?82%.R0@+DM']PDXQ
M5(/W9C@+7$$#BR]@]D%*>--7DAEUL_<KA '^N69S[/CU\#$'X,@<I$T$VB*F
M&XR>'HSW:-'8W 'K"46 !Q'3@SZ.=SH^)]_44>B<A)E/%Z0%ROZ=PR2D")&P
MJ$C)'-)A</^X\2[6XGY^#YK5:_&\T;@B_ Q#FE5$@57X#1?BG<#/-K@%;GU<
M/7^TY#.$>$_Y.%/R_ZW9741:>+I/-O&8JRS*L#X5#<"$XCK+>!TBI"^A=6M?
M'^'@"1=(Z&+[QJ?P2RY,8B-):"KGLD&9V)V*.PBQ0Z#AH40-/SCN3,^C4Y1I
M0R::-\2Z0="K4(C[^YB$7N9/7LX2R\VE?#CVG'16,PJ.=GN:L(&]MFW@&(\@
MMC$-P9X>?CQX!'AH\9NSLH##,EY@G8$P !:.G.23^[-C3H^8P2F6,D@_P6P$
ME^S!66(;O#0^#RX'2[^_ 3#WS/OG^[\?O;5) ;[B!<SHA>$2573F%ABFX7I0
ML[6KS&$C*JV%%L%D$7X>WO/YU!8\X3$J15<S7V;G<7YF!#9"@V$4RU_GM<B+
M2Q$KZQ@B;6"ZJC!GLL)M +?.B])TK]Q+0V!-GH2P;$ EJ\ GF_R&#3FM2XRH
M_CNL!5"O]ALN'E?O ^^AY 5;VX6\EC0-J!V&"VZ3L^T0U7=;MJ%YH^<9<*.T
MB!.J='&),%0%0HE2T+ 3])E@]:<+T()XG:W0%TSS$G.)>5PHR UPEL<-VI9O
MX:._C_#1W>H9CY0RY1#T<+9ECW,B&\7#;[<#1\I]VX0/-! ?UN9#KE:*ESB*
M HXRP4'!%==84Z:DZ3E6=:/X =EDGL8N\'O;"B9LI.%S9N)6DK,7SJ&9I$$R
M^D!$91?5TW[T>1F6TV.R#2;9F-A,;FZDDZA>6(H^PHF7I3]ESN$P &O,DK+#
MJU>4HE^NE@W\@R)]EIO'M@(@6W_4JQ(-RF?C:&UB"SPB^RY/@L**,X0))= 0
MO X'B_T7\/W:)H32P\V7V!5MD11,&)REH>5A97Y,R0E2"TVB0T$L0UG1<(M9
MUJ'>@*$)2TI&% 5*>0#-0:E1=AI=N7BVF.@E;OKF<+RFU7GC4+8'I;"&=)R6
M*]*7;*6Z #/NRW]A>C^.$ V<Y4:T,R!8\QB?U+J+(T)L..,%SBU#-J:<HT&A
M'D+@AVS$7;A5JI\L%#GMQ:+9+[COQQJNU5E<B/D2^)&HJZ956!N()V7CC'1/
M@DRRURD#]41?J565[OV( #8[D&K24'S ;;'4Y>/$ >:2$'?=M,A7'"2ET"S%
MDJ0=',CF!5Y9M5#'AN65=+/2R% 1PR)/K5BR7,]SCSFHU9*J3-F;JW,,CK/6
M6ESB:)$0H(=Y)R+^UF>HN2WN-Z-R$.)D3*)EMJI<Y)D'8=3*/;C9N1?6=GCN
MLE7&OD&%Q8612(,):1'*3$GXG*,J2:BDJO:^)1JVG2D#]?RQ,C]\BK_LKK-#
MP5?<9L(#AMS=8=6_VI>X(W\%LLACUQU-0R$4.@A[9?<H"!9#QNEUZ-YM!H'G
MC?=PSG[Y9J^@4X!U&DM 0\=!D:.:Q"*,X@37R\EC>@)LJD'8!UIKV%LNIEAD
MY!7&30K?H;*BB]0*/1-9S4I\6],Q]G"*)G+"]Y)'0'>UL\0(ERUA3"Q3 TFU
MS\0U5.:HR(7M381XEYG;JA5 KBMW&/FB!_Q(Z8 45_8<%LCSNP)=C8AG$=U#
MF)=,<58FOA(>V="HE@8NHMPJH52;F-99-$,'"0%(C6=!->A>RA6%FYX?I04C
MKR;/<:#^$DD&%_+V"YMZUQ+$SI7ET:G&N]^P@:@R",[+9=0YI<XK!XX6R>XI
M?:##0A4$BYH^03X%'Q'QEN70H-4NC(BY]G--4P3*EA2HHKV(M]:(_5GO1ZVM
MK[O(PROE';K2>/R(L@) +"1KPHIY#QHL]T/?FG?Q)2H5\V"2:+0G7)88(VO6
MSRF?]^PQ7T2"Q$>XR;J$A3(_**+(^H2= BZ#[=GPI#9V[ N!-IJ,[5)-QH]V
MZ21^I(4-WN$^^,AK85</Y.,N3D+QH0;'+UE*"^NT3,E%2_C*.=M4QBF5=\/-
MV3/8'9R<ZC IFI@!)?.MS8,%Y,EAT5]'6K][V,2FX,D?0<)E];JK=SZ[H=V@
M -=G$PFH%'1*WFY2Y:&G::8.X=B'*UBFN>%SD1>ZSQN&[1?;H$17)WS<@4IG
MQW)H)L5JBN:/7*SMRSYS:AE;"RE89.2B:G<Z;HR-3_V/N]NY0V+T^>,4H[^B
MGQ%F Y>(#>2V9.B-1.E]L1_^[,!+&)XVRYIR^Z(?)]'!DX/O';** GDIHD1&
M/_ZQ6BUMPR@F-XLSVSAJ4UTL7T59FIL]&SMX&KRZ6L#N-R6\O3[_XQ_@:7^B
M?>,*;#N_(N-2FE%8@B=QYMC&@*QUU-P@*MLAD#>*WV(%<@F4*=S&50J6!Y46
M*U85B;WT2_#E>J]"WM(P+#?ZY^^?OIB\>/'RP3%N?HMN[1!MUHM[@"']%I=$
M%V<V@(WNM $!!]P &/,[@(N_V']Z+71M"+5%?F_,";'\@6#E^<$FV?4:;#0X
M?C1)8K&YMN/.X\]?W!W^?"MPL_B%IN@?D\GBN;GDJ7)UC:. J02]'Q.%%.Y-
M?&8SFW-[%65XL0W#S^S<)"NP)9[N'P0UB- -25Y*]2Y,,TM4CE&8"M2JHA+U
MCX8? #TL&T>CCQV&ZP^[V!X^SQ/'4F*<:K'#135SI*4\0!T6>@?=OK@4KYMW
MR[E<+G?=4#Q+C3I0K73!]I#.W&YOCAUV!LV*20?C2@?%6 ?8FYW+F'*'IB?\
M.Q$8]?;+S,\[_FFLN1U.J7CQ %(J!I(ZW?N,'F0]?DR)R^IR1THK^]HMPP)Y
MK'TQ6GTJN<6GO9.=A;"20LI+Y'/8R1RLGH U0.7KHL3,8PR)BB-> J3D/?>5
MI=#IF!;HTM7"9PTM%?"G3:)$#5YE=6J?-(=0P_1'\F [.H8P^16_<\@4W7,D
MN)8"#OZCIC73-;3Q[YRR&,\XO@[G XN.H@P"_6[D5,4;.WHJJ^0VPWC]T4LK
M'KFKZIWMN !X]CA4$'L*DL>LY_SC[6TF-J-%[_+FWF6#FA+X@\\IQ1J9HPV?
MN)DYHYCB-!7>>[CO J8N"7*L]1XRB#29&:F_U")PPW@J47,&F<DKG4DD3Z#V
MR!ZWB>K3 /0\C?/?$3,U@PV^*,H8%)QTM5!T:%F,M$0L,W$[$#RZ*,.*FY74
MI81N[OA:__Z1K'6I/H#*+OR78\:[R56E2)//5HMIR>0 XNUJ\>NX:F"E9,AA
MF(X ;RQX"1HSQY>XJBV-"I175H)LER6==!6&:):H]#WWQ%=C7R;!C9_S/S<.
MF$KQ,/4H!NVBC>K((5H!<FA7M0.9=?3_,1\+SQ_)5N%M0E10D5<ZJA4<%XAG
M(Y%]%F,Y *4?X8UD3=!B(@8H%.EIO>Y8.*)>=A8@5,I->->-O/;BJRO/IJ,G
MDPC_/U8KA:9)IR#CRL5LS)IC@H2WL!L#%1ZS6#*9%@_JCB_4%]LNU&CPU=EI
MUJJU23#*IEDK!B_)L1;9RL8JUFTU/LCLYC0V2Z[*P.RN^L>-RGJ!L+XR5YI;
M[%HK]<B]3A-J[;>K%[K9RQ#TMJ.?N$^YRDZ(Z@UY6S;62[[J%?>SDUX,0T2&
M>^GE$$+_Z[L!O)ZLN(TM^#MIW+#E<<":09R V5!1QE>>.#HI^#5=+)')J.4C
M<"D-J)LM)<7YGF@X!EPH/SSVA3*YSDJAM4$<75+%4TBHVDO(FUAM9:);-2=$
MGB-(ZR#\W/DU]./N>AX9?E5%CNROR93"YM0D2/KQ5<-<\;.>Z7<@,*%(-9O)
MO!I*P,XOC*=/'H!TN8XNUQ^K"(KD^:+ 86)^BL IQ.C"LKMD 'U3&4L*@J,6
M?DEH-V;H86HF276Y?1G+K?V^UHPN#:8UT_=A*U7WK[6RAEHK-T,V!074,'Q^
M=4._X4&^9K;SH +BEF'SKR<:<,MVA3(7E'J*@+"$Z=J<+K#)_*"@AJ14="NE
MPMQ0*H98<F:%,:BK?'DJ/<1:/*W(JY@_NW_8;!$ C;ZJ[D%U2;O5"T81L*:@
MHEU=H8R&PJ*@@5<_X8XG^<[@NB^&C&X_(+3N%F"J^Z]],I3'[V!XT-2V7) W
M-A_$F7 =@-#PR 4EO(=%+D K^Z+N?@QN''[O!"]PRMP6X 6NSAV %_"C.P8O
M!#[Y 3 @Y%_='L#0PQK@/:,8+:"JD%<K(SLN0^[H8/C:DF0W4 _$LOX-]7!?
M:_TA(7QNL]9O[+OGH(\85PV^I2%BO,9LC/%&$G"[02Q6<2<3B8Y48W"ORWO[
M@W5=)0@H)R1RN)\)H4U<3M.ZE%^8MDZ&CW>$3;BF?8T^J)DQ.* [OO+O".^S
MO?KOY6' >@QS:;*YI053\!<_OXJ:^+?S H32W@?"M9^NIA6LVKA$PN')!A>%
MW44M9X3(VU$K-.H)#% 1U4O>GAZNBAQ>$+"7$></?&+UDP8IXV 5DQTHZ+I-
M;U2('J115.+.->KZ Q1P@]_U2/FE9]GG>M>1!R2L*J9QLA&+OFB5^\P5SH,/
MC[XLLR)E/(._20CKIZJ8@2Q_%K*+"GF\)09&]6&5>RPM>_:$OK2[7^NQ-ZH<
MOJ'Q$E X<-V *D"]=J062()QEB,&;4HQ_Q@F%F0MY4 +Q_]U"]?@-,,9!6U6
M_<\3$(0EU9S!/-'$UVJL=,%  S<7BW1F-:7$5B2QC# +3@J10DB+N/R=Z?7T
MEU=7"F""K/:=M&[@."-<8>.[-+>IKLA*.[<^IR9]FN^7 H8PS!M& %9QF69K
MP=]ASFO"U(9(?14,<2SD0_#\?(]9<^OV,%;,%^1?ZD[VK7>5G"I^L_O,?]1
M'=\!N54=R[PO[*F7O5L3R'7?NQFY%I?3;L=BPMU"+AP\'E?0':$4;W_ /Q#W
M+B:XW;=[]Z[7P-8 P#LU;SHUL)M@ :5\3Q@V9GV&4=6IJA2'P#P2PK@*-+T9
M5[ @M=_7U U9LOA%@1/-1GW(OI;;YRG20R#A@']0P'^9F#E&M;#!Q+(U\4::
M[[<W+;R7CZG,&RR1G)K9Y+VGHX :G%YOV0ZS$+_%HA]7+'HPV3,(8/+>I0X#
M7Y'+P_%,"2<K%4I(J^LJM[&C"-3.NH#K=MXP!UA5I8:Y9RH2O:G)4H/FP(RT
MQ* TD_656QAFE((>B&HY2K[S&+V;U!@5A' >GM([)--,?#[(&TDQ^;(KT[I!
MI:+9_^$IE=1#T/VV3GC*\I:,%TOBU#.^309C[.2BX]&K/$-0*;%;$JO4IH<J
M0X-H](KL@A7KIA-V:W2V0VSM:\J&W50G!H&VWM^6KB6,U:@9TBI&:DL,+C"\
MI6L,]I06E-4GN03:H&K6 ;FM7KF9Q>=!P@QNZ6&/PG_N 5'P!C'0H+.9\AYL
MP_:4;,-JK(OR2OEA70U[:]GV(L@[P2@R<N2=M<O\\GX2*CRJPBR,@=5/NR4#
MGSV\LJBQM9S7C#;0^)<.GPKJ)4X5T8=^-2N63@GI@5^_VN7SZ]D#B6S??,+8
M$9*O>7<AJ^\$W<_)!!ERDA#3B(H.\X_/58*<<[)93&-')6Y+:GX%!'_"FUGG
M&#LL_M*ZO><*A)*:ZE6$C%6[O'3N*%!\BVV?][ H4"2GY!R<P+E0$=;!Y8%+
M?+AR@>%@QLB98N?5LNQ^Y3R;.]1*!HQ^WJ-J<L3'>72O*LHPA1?^\_71QT_1
MX6ET])\?3XY.3]_]-?IX\N$OQV^.WD3'[Z-/OQR?1H=_/CDZ^O7H_2=0U(]?
M'[T__7 2P<=\W?'[/\-51_(-W/7Q\!-<"G>]?^,__(_W'W[;^^7#;Y;[&5YX
M?+HO/,;1IE;P5FHWY?83:4><ING]T3'TXL1W\/T'^\O14?3KX7\<88_^&IT<
M80.A 8>?CC^\/YU BZ&[;_C+WPY/3@[??SJ&:S^\I4_^X_C]&[B&GRV=BW#X
M?OWX[O@(OCI^__K=9QI$O%P^#A_$(_#KT<GK7^"SPY^/WQU_^BL^I/>.Z.WQ
MI_?XIK=X%<S(R:?CUY_?'9Y$'S^??/QP>C2![KW?.W[_]@3>3.-)SSN-/GV@
MR?S+X3N867P+=T/F=*(F%:Y_\P'>]OX#3MSIYU^/9'Q./\*X'$LK?_OE\-/I
MAZ._0.]_@T&@KX]>?\+W?,9FG!Z^@[_A61]HA-X<P]VGQSBT^&I8 V\^O_YT
M:M? ZP_0^A,8>1@NN.?7PS='T<]_Q2?AU:T5Z&=0+4!82:\_O'\/C<"74*/"
ME75MZN>;&86=\O3%_O.&H765;+LU6R:)+V+UX^,+"QTC31WE:)'WY@/!;]Y0
M993H3;R(SX+",@^*]O+9T_V7VTD^6>EO/[][=W3ZB;?QI^CCT<FOQY\^P8*!
M=?7N\#?8*+)Y<1/!>CY^]R[Z&:7=X<_OCNQV^:"ND'TI'QV=G,(J>VLWZ_M_
M_WSR5[P+E^:'4]JK?_[PX0T^5G!6(& ^LW"91#]_/CVF?2P;@3X\@=WT_O,1
M;$;X%#8Z[4K8W\>X[-_X#V&5?SHY?(T_XO[Z"#OGT^?WQR0B1B='?SX\>?/N
MB)N ^P+:"]OH\.0H>OT.]O/Q6Y0J(!'>'/YZ^.>CTS$]Q78$GGUZ]/]]AA$[
M/GQ'0@Q$-<@F^OG-\0GL+I2,1R"<#D_^"ML<-CU=^9%:\!?>\T?O0:"]AM?(
M.V0$?OOEB ;O\.3XE';ZYT_8R)]/C@Y?_X(_V9Y-8"1//D4C+T/?'_WYW?&?
MC^"AT-[33R?'(&IPJD@83>PPZH^LZ/GM&'JOGH33"CTZP4G[]&&",PF=_Q7;
M2S?YUH328XP3I,?6]N;T,US.<WXB'0:A32(:!OX(EQ-W'T4LOIV7T^&?#X_?
MP_K\[9</O_IVX_$+TW3\*PS>+_"0GX^.WD>';_YRC**.V@3WP[NL&(:/.M[/
MXAP$.$K!TT_PB^WYV\/C=Y]/CJSXI]Z]@8[!^^AAL, BZ!_/OSU4]OE6Z,^?
M/^"#WAW#5N)CDO<-O.FG:'0XC@X_?GQ'VR X@7[^JPR W4EOFYM+P+"G."='
ML&]??_J,KS_Y +,#-YP<__D7%ON'C>O];-W<Y\(GQ6GT@X_J(MD'O.7&SWKZ
M=/_IL\!S T\9_3SFH6JVVIYZ;XY^?0_;\?4A'XL_PPJ74?T,WVW1#.M&^C'T
MD']M"4SLTOCF;Q3ICX4B_>4],)2[6@/X@Y1 O3Y5^0.PBE_N/QV\@L=]6,4X
M_KMJ!W]28:HF82 ZXX8L[M,8)UO,Q_KJS[ T6ZX3\5C@--@"1R$K0T!SWO#_
M<U$\9J%^:Z;E"M$Q!T^H_,@S"=;VY_V-I9 ?%L#]L@2KP(%Z. >0,*N6IPJ^
M9\<8MW'HH9/Z(O_X#_@_ZV+K&T\)2(. S%)TQXIX,(GRS]X:AZDD'[W]9CNO
MMZ-V<B?1>7%I+@('TT02-AV,(*BZPH'Z>(7(52H;DZT9[LHP8\2L)DF*;88[
MJ+;5Z+FM0CWX?.G2+UU3E+*K^Y0QSM&O*<Q8C9@'3"";(JAC88)0LNZJ)R;A
M89BO2K)<%7##&$1S$4\[)6@B!7O_TZZH1,,5!A>,E+;?!G"SA3%U=X<(1(&L
M[Y@-RZF15&=K60=T*#9T;0MA];95O43<0V[H;,@O01&02(E!'$9;C^?*Y3(5
M@'3BJX3KB>1>=.SWW2F:]7+_X-$<N:KJNUU'NWH*NWU@-RV>,L62P9Y.?K<"
M:+0>;=)#7G!6B.(.\<R[Q8R!^;-FP'5>9%EQ20D-%XZ)6+:6C_'IX'W8B)T*
MI[\<EK#@A@N_0;2L3N!A2G]XJBZRL'&2'1K/P\UE[F],0S"Q2&<I@-;W?,XR
MX3!1V>3&N/3<&)2/V4&-@8/A59S;CXKB':%AX5ZXM\WC-).*TW!HK&W513CI
M#%9=_-%67>2M9(\N9.<.MUW78=8<'0_/5 1T"1RL-M$[Y>J-JQ+TGS#YE#28
MCL*11=X) QMF#1$]> VZ]1F6DN2SMS$PU%A,SDJ+A."5($ZPU*:D )-RG<$H
MH*A&M5I D2<(?&2*# *APW$O="DU5OL^&WH1!-W:84S)R[MC2]@>&' ]N>:G
M<R@!-XJ9)0-3$!D#1ND.!6C#=(IA-EZ85$IIA2",!)=;FK-5YN ,]DM066>H
MX9:$EOD;**)5D@K=2 PKNR8;@G)X'+<!9T@0F#?GW^;T_*(\BW-)Y?,#(%^C
MIHWB\,PEJ%N.F7BY+-*\=K6&;6E:JD-5E[# .)L^56(SK2C!U22V*CHTZ (V
M&0A?Z(EKML5>I#5FD62"/<[7NOD^+V3B2^SZCG.62Y)6B[2JY'V8&8A5**/1
MBU!B^@G2,%G)J6IT@11XK&=?<*;KU#33Z.&E3G!02:[_68%(Y+GI>MB"^6(D
M9Y3&LZ/F."I;CG>"'C2:CH6<[1+N6>]1+<[1P?=CL$IA/36$_X22+)6EY1IA
M)P"6MN;.@(&IF*3 #S4#8"Z%PV.U%."X[^[<\1=_%5-;CZ5<6;G!(ZF/*Q-Q
M63R PI[3PV$T2N?Z0%NS;\4]-T[0V*RIPKVDM,ICYZM:3AA-HD3JL5=8Z&A2
M>1 >L]\F2>_3I@-!<;N\5!TSOJFL(PD/DNWQG%</#LCVU<ZKY\%QU=*X4?7$
MM2VE\;*U%5=KYP:1O&[GS(!]$I!(Q$/9#KJI*'FV?M /6ZG;K2+GVZC;=CQO
MHF9?:V]]RUO\NPX8WK6 ?'#$."B!O$&_R5/@A:00(6RMVK<  M<3'-U*Y_7D
MQN!RXN&>P=>D9@BY= ?.H>LZ]V;% GDZ+ ^R,I$4?>+->'=Z"C1A] *Y7O"4
M)((^SJ"C6K],U,Q1#CEO/;4*.JE*$&F=.9I;*7D]+92M$(;XE.2_Z=:"5OT8
MT X-T,:);<[ 7C3?X3MRI^UV/LC+!\.L<7I/OIX@T0^C%J4YXW(,JVEE;(*)
M#61O^]*7@?(J9B3T\3R=IBHEGO $9"XRW287(,)KF:PR=-W2EI 2$\BP029I
M'_4KK-HLOA3"#11&]7H_>FO=0AT.X-8&Z#!T;W<V5U%@Q=%T;&,A!*J.'UZT
MTJ>M*I1W'1SQ[[;0CECH4K@JAPHO\J7$/"PG14?8K8,I\\Y+D-UAD/C9XPT2
MWS_Y^NV"Q K9<9T@<1NRU!,TUM61;A0XYJ6OH\>/,7#\$/.PO<=Y@NO[++V@
M\PB.$!-7-5*H>+%T#H< *K:D')%3.QH]/;!Z&1>D;"P*JW=I8:B<3SMM$@V:
MFKW[. "E/SP,'  Z\8?& 3SM]2^@3C<T#L"8:Q@NRBK^A@/XZCB ';<)[XPC
MX$[DV? VX0[%_@-FA(%C_TPKNM.Q?TOM,4CLWSYLV]A_9RP?R[[X6/[U0_B^
MXP\BED_TX0/$\J\;PE=L=S>,Y2LB&#-4/'][M]"SP'.QPQR]05>^>1+OT)/X
M[$I/(OK-OZXG\5NP^UNP^UI.Q;:_:@#)\_W@3L6[]BDVDGVCWO9O<6*_1I%@
M\C/<^'\15KQ=]4P*WV-88V*5ZS)C+*8.?6&P=R"<1 9_,F6)^M=:,>6C?.L]
MVL'(WI#UPD]5;DG6H[UK8C"4@K;V)\TB4,TB,RR)/;ESF*W76TMJ)NO$<&$/
MO(BTIRQ0U36WHK@,F!I/*)4G#8KE";,O3BP_IJO@!88#W 6Z\'FZO(*;D9V]
M55K55;,*I&TI60^N!]$(9P MJ2%3+86UVNXG[=ZWZ9;[/JA^/.=:2'9>F+FN
M\JUM/B[H9;./=+,]NKMO'_D2>@Y=P)LA=O9JPM8=:"#+PN3QN(EGQ<U0$9^_
M6_?67:36?: ,4V-\L9-]Z#@/0#MF7VVX[PJ 7D_X_9K[&!KE[':TN4=8-BNZ
MI,IRP0-0\]\4X @9TUMS@ ;03UA3JS$"=NK;DQ:6KBO*5US72G&K7[D@KG[H
M5DOCE10(Q=JCG>MX\P+F$;A!H[=;OLJ)FR?5]LMV$E+:#[!D]1+H6+?.Y=$:
M"'%]2%6J^2J+1K<77^F^V7>8F@X9.X+]H-QKW2TK#0&;2(F(7B,M8S565K0J
MQ@F6-[*0@,XJ"9YSS17^%D^I9;Q6Y_7V>.+ VR[V#^9F%_ ^D]#.;QR%7%FJ
M<^#]H#<9T\D$R@OO#B@-K,JE!E%7#)OV&>5R/+*OVOKHFZ_=I93NYX\B6L_D
M&V1[J\#]*_V+@J/>MZH\E#OF^;U74/],I 9ZD$L&Q;@AQP/7>R+\R3L7I94+
M@71D.$CMW@!=H/1')=M]L4*I?51AF*BE>'*]PLI&[VCW$UN&99E&W4&.)W&D
M8-5$<3JSR' 'QV9@%6MTKA)DX,3V)5C($4R.=,S04+&_6\K/@R[_4;4J+U+Q
M?UXY86J>A \FJ"AN#TW5/]4M\>IZ(,>^[_S[HL83ENKZV=B>\Z)Q\4&KBNE6
ME4&31ZY-H2Y7:;8:#0*E2I&QE,#4 TU?%&BUI(A2&7>5C?=ZFX*,RJ#."K"#
MJ'HDM/RC=<7Y*E_H;\/SJ<F2;IBKY1C%03I/,=A)( IK!#LJ(:HBUQB,UA1A
M+^#8@IN1R63TE(EIV#]X]>/N<&Q]MZ\:Y$!3LV,+A^F,@4I*#8$O.>305#X&
MT*@6*P09P)F_HO59R2X:VS!:V',K*L1X<Z3U>EO[$=!W4J"M--52JV9J,80+
M2)0/NBB88-9"/*&/4H7N?7"J<RKS--7@1A#U7(.UU;Q0\M(4)XT*5<T-.&35
MHX;"Z?1XV\90@@[YYI<A/>;49,7E74[6?L\YZ\L',B=:L "'#(8UACK555Y(
MU586BS8^VHQC2GKHZL&FGQGD]A@0I<G@GX-&OB(NG!L_NIMC)%QR*&0>QGGH
M!Z!3B(4+9]0JT]S.YW$AM*O7H8"IG>VN*X*[!S;Q4M.UTEAP-/%=?CF-69%S
M#=29Z]R0JM&*J5D7S FFLO)O<,+>W6YJVK>HGJ7YB@N]QTQ))J;JT9<E'U:#
M)0&'N;O?HH7?HH7W;1MO#=*-;F$0OVG6Y R!]_YT:YH$RI\8 JHQR$+(&8Z'
MR&_DU::\_E6N:FFB4#XW63(&2<;Z)&S[RR(:'8Q#,8;GC"'BQZ*TOLFF^$9%
MNT\KI6+F0T9B3JUP;N8P1N&+VQ&:_995Z8I/B3W%=FJYWL:88\Y(>W"$ ^0-
M+^9X^=Y2@M[:].KRF-R1??NP32\_$%O;8-V:2M^<<O6R<.5K"RR8Z=TPP7;&
M\@H12W^W)E@ >.U=J!M-IV;LYH&83PV+Z>_!8.J4/GZ&^V;WUJ93WX.W,J(>
MLP5UL,,6U(.,*+YX1!%%Y.CW1V;U( *'VQ2-N<V<]M!YM(/PO!>O-??*G^2U
M_0$X1D(1;F-;QAZ^C:CC(*0F**A!YLD;G/P8X-F(F3&(O+$5=3%+%]0R#U=A
MB <?>:UTVQ9@;A@ :D]CM0FGMLRP%#(6DS=IZO"GX9!8Q A:RZ"64^YRE'!M
M/FF-52P':!59>\'\(\7%[9]K396JHYM84YF5F(:Q09@79+>-<X\$U:K<A A*
MX:!RA[QD[%C$ICO:;0A=FX *7858LAFSZ$[C*JW"B%\=(B_:JE;"QVJS^4X'
M495_X3GRRPAZM@=OQ6WWU=;U<6Y **?8?]70NUG9\L17FRU*P^%V3"(C/Q'K
M[C&F5XV5H<;,#77&') "XN4,$9.9B]@&Z]DRX/T!QH3%&C9?RK).@1DU6ZJ=
M><S@6LBE 4D+JL"X'7$8.^8=5\]$9//&A&^=8ZXME(YG3AB#@$-#[ -+7),=
M@XF#\\64,R2=H!8XZ,D0NQCV1W@X!"#H%H9EB'?Z;9ITCC68,(WS:M( X)/D
MK&IGP 3X#^VA<GMZ@&8W+8EN#<-+$3G<0:"MZM!8XCKO5]P>*@NA:C#FM=AV
MXMRIL.GQ&0PPM#T^HM"4,ITG:G7#8'YG4MDMO4M#L".'OJ8AENO.FF@O'X6)
M=CB;E2L,3/@3X;X-M.V3H/J<'5T.)3E4\1"/8=>9E$ZYCP3))V64$F\4"R8*
M/U#WD!/D*J29=T_U.F#V(X)]]CMHNB%J&NV)/Z_R99PF4A+,@\<U1;55Y&?%
M O3:!6:P0C-!10'ED54,2W9M49I\!Q<<0QVQR-E%ID9#*PU<QH_1XUR:S)YL
MU#;A^]PE//</CV)K\SD49[NZGV^Z02:W\*F'$) ;/R>D)]CB <]O=_N+V[[_
MQ?XM6_ R>,#>%O?_H(,:88W1"=E;6\1B!L"H#1%M^;XK&<>!R0.;076R$?2@
MHM7;="8*YV:\Q>S^L'_+#1*6,-_J 2]O^X ?@@?01-Y,**_^]*.2I7LWOOOI
M4W4[J2 3.\D9&0*)F:=Y*A:[#\,E]BSNH\[N.5OO3C1'WRJG/YK*Z3_<0^7T
M8W@>P6.P'.W'$C%#H':?D,MHIRJH__!(*JCST*. .5[@X4HG*0@A]5N0-78,
M @2Y!?'S8V(L> B6XS"X1YS3(6?U=KQ,XD>U^75MT",3;MPBT:V5MW&+9W4!
M 9P-6ESFG5 Y)HBC;] "G8)I6A H@#X>.2^XKN!640$+BNEYVK2 [H-OITQL
M7;#)4CO!Q^C5Y] C(=VJFEDSR-V+U^FMP*N^O1NTMBE! 3K*9R#1TCEH<L1$
M,H?SH2R-$!F6)JT08J*OL9GOH/[1\XDWL"QJ6Y/"]KQ]#_6?G!>-I<(^Q&?/
MH\_[I_NO]PF1^_)5].S)RTG'IT]_Z/KTX =^2>N;@^??[QT\?[G?G$OSQ<R0
MX9%:1J0'/(%ZQEI3U;YI;(D4/2&7:,:L'2F4FV,79/9 'HJ42%5XYAI$LUB=
MO JKIR,AGJU XA%!BK<0VO '=O@8M$IR+#F([5ESQ*68(@' )+(U3B:HR2%=
M" ;/)6+$;#"ZA>H(7-HCT$^Y97"QW6>*CM0HT^2R*+/D$M-$F_BH<.52/TP2
M[@.-N(FGQ07!LIA-L2;0AJ,0;V&KW78AAU&:[P_@!P:9\U__^M_:-;W3Y\>]
M%WEO;$L0O9VB3_%#]LC SH->6(J0[C(Q%R:#U0L_SCB>,6%ZUV0UXS6WI/1F
MIF;&Y9]'4P.-FFLGXHZK"\.7:[@MUUJ7XC;L-EVYT7=[UF%&XA58=B"J9_#[
MVC*54Z +.6_Z^*SV>\)9%*='P;188F@=EM1J2:[VFRLJLW-8E[#T88<&:D_;
MVQ[7=8Q7DTI"KU15&P15A"NZ'3@@UEJI*3EA2I1Y9H\7X59@_R7G+'?,5)KW
M#-!13%0I^"X*82"<UJ6N4"@"!'H5:(E)6LTR)/45A;)0[4W"3)O@P+F.]K.K
MT;L?[E] #TF]!A9TA1H4+*O[-L&V]2BU<K[BR@6Y&3%<<LK4 $+,X\MX9&@G
M-= U#H>U+ W(+&+68"IM2E3AX:8TJ<2I?=8&$%5/*ZP29[.[6^1ASS8?!,39
M8';<MYVUE"L5LG.C86+A'C#@JTKDG>7]M8@5"Q-;^H4F8"O1+Z1+K$7,3<DJ
M<K%<%E4J[.TY^C?+]"+VU0:8M/N&<]JY%\P7.EF,=:Z"%/\2VU#1(&^@GO%+
M*O^6B]1<PN.AF_4>V5W^,Y*CRZ6),S( =5D.;V.,;-4K_ BM7:1XNX@S7 8$
M,)P5>2X&@<,0]9V;:(K01:U<A&MF/!(;94(3QFH<KX($;-HU?B"!"T.GF:QR
MM$O@$RXFF2,[D(2",23.N0K0V;ATN3']K9?G_V[,4OLVD&W3$%&86G[Z^7,-
M 9.G#@(G9$%(<\WQJ""U4BDKM-(Y.6,M1A31]\R*Q:*SCYP(\U"%A5W?O%02
M$'MG\*IL;24BSP*RR'GHFY2YJHK,D,H!2A/M>Z2/Y 4#3TM+V![%C!8=7E1(
M:L@R7N/RF#,]OI]C*UPQF6KF2/*7RA'9-7Q7#IF8UKJ\1#1B*D!8JQ)K%D[,
M,76-? C<_5F,P-V&?64GW$VSI<452$47(NNFX2.?XZ*+B@J>='S-D>'-V>BY
M]V#!J/3HHQ[3HF\>6R1-E!7YF:&R$>A@,4E[U%V:Y*1!YME^1.,D[LP9LIZV
MFA7TB27EA&<YT!V.0Z=O3/-?D@<0OOOMO !K9>_#)?I*3E?3"O9[C!X7A<;C
M$=B<F!:.;DAY9N&_%^.^2Z<8"I;UZU*@U3%^Y.A @XPIIO"'LZ=8X3>X9<A)
M!4]L#IQ]S;0H<]-@4'8K07,RNCL]#9<^/) M%F[$*G4-9-3AO\2+Y:N3Z,@A
MI-X0[=MAW78JB4G5VED4>N(<9&)-W6/65) 8IO2$:94^^#0-0'!([0X&Z8?[
MK@#9:W*\+\3_S-7H-,N '?W]+C?>0S8^VFE8@UD9QJFDB9E1G99K'8/A27OE
M67@+]:'K+-2(YH%2,0<TW/R06A0G,G2XD]=S37)E)$KI0I=,7)$R,C5:>ODX
M@-<B68"Y6>$*3.%4_(&(L?ULV&*@EX18(QPW >JQ@ETA"TO2I>-V43L"RB<A
M,S)W;H!!"ROV3")L%MD!Z MRB,Z)L#IOV^L96$",2.'N[V_<^'>WE0<8,$5N
M](W3Z-XJH-S)H3I\!91[2:OFD**M4-<R?;^:"["O5LU=3=[P6)O[F\3W9"#N
MJKOV>!X&/CB] %2/2Z$WXJJ&<W2<!E4BWJ;D9X*ON<Q$NP*-O1DA$LZ*=24%
MVAK,Q-HJT X6@%HM:$8\5+)G7YD"LC3@:-N(K=R=33-\I./^-LVQ7E$=H@^M
MV4]46T/B!?>]OYX^^6&X>7QP!= M5$U06#5=$>#6O'EH/2]MYC&\^NA+6M&F
ME!GU+I;*Y;"BXZU3M,AGC<402!Q\;:-$4F<E"ZZ86H(N>[6VS#Y<MB]4/1?\
M!E/*-+1"-5:P%1Y>8P%"]*!F']@4$311A_2SYAL8EUE<QBA!824F9_PJ-L2F
MH* AM]$TZ+ZM]8/8*"RY<68J"5"[,E:Z@A@5K6*>PWRO.?H*IPAJ:3'#!#,%
M+>D+7.Q'/QN,>XB;?!;4<3)*R8D%.-=P#6%4 SD78 S.BB+!ZC3PHL 1U,*G
MX5S"ZQ!,D#(5565J!L/TOI@&.;HD[B+A!YA1,J^R(\EMAU[ !D8SGCMDF1U7
MA0ISX]JY@BMQE,[.L4XQ1^VP:)@=\AF5FNF_V14J*HT=)RS'FV#I8$$@9*EK
M@O@0!9_A(TI83P!C5^SWQM$M5AW^NX!P,R"MKVBJ#VG"*G%.&\_\9-<+3QP/
M3$^L**AJ%H=.TY8W<S\TI2>1JO:F F.AV3I1#):JNJ[&6#! D>Q?"]'CEB2F
MFI7IU/I:;L.IU9#W2&5E';]S5T+8N6EMDZV;J+.QDW X7.$>E=09QNE ),29
M8Q#QG>/X\,!EDVEGZ:A&.O?EKHAW@VL6*K8)RI2)N9AXZ+4(Q87M\-\*ZPV2
M^>I:#Q;8$RP)A@T7EU(9S;4+%AM6>-7L;RJYWQ6FQN70>E$>+] 13NF\R!;(
M!<]1,L%U=CIPUY)#$., UB$C87/N%)]5&,\5F@J8F\5T52K8ILL;QI"O?*DV
MH//<=P2;_3I3BQZ>AD-IEXEJ45>-CK9_/\XE9B,URMMM%DY 2L FU?WF+6^T
M3(>XZAHEQ;J2ED5S@[ 2?&I)=@86!9</N;X:_\P;2\#=YZ"J&W';\>E'"5H4
MV^+BW!-]_+6(E)IT#P^ -W3WU>.MN:IO;=L<JVQX2ET +6-B[<M8T^\ZP2S5
MSW@/D/5,B].9SX%*V:5O=3GRE8$MSF?B\+Q@Z$>/ WJ&:),D+MGX)5'3;@\!
M@7I:-"&-R(EC/C<4OD>7;5*D2/4YP85SYIB+&0@?/I?0^J3ZMAZJM=HX5.L1
M96J/E=MQ238/80;*6\5J'-6$H>+XLI_:JC;+RAD(OO?4ZV J@\J+HSE1[<6+
M90:OF*[MB.(\L+# GS!<M*J8-+11Y3,Q60H'R:;*O))^03 MK N)#< ^R(D8
M&C6]3;6Y*BY/213QV,M?%U)N4[1S15)\:W 84U%USLWH#,\H\BV,.90N8>T:
MF\%)?[+;IHSF:X=LB! M--9<6=YY*C8"3W>\Q)2-DA:\OX@4<@],:/+4AH^6
MO="R2D/2LC9)V%<P7P:V6M06^+KFB^"2>LT7I9YTU@L8U&II"(+-YDM@N3KS
MA34-)VBLLAJ8:]O;+[@G\\ _PYC-H:R:L"!!X\R6W,/)1L6?O2%7*_Y7Z/L!
MZJ0YFL(UT7%M*\1Y&_7=#P8YP=IC?SWU7JG*?4KR[;7Z#6"=JY5Y98"TE7F5
MT;D;6GWDL>*(^(:[$/"( E3MW&'J]EQ+-_Y6N.=;D+MI"SV.:L3-4 ^%=?8X
MB*>)(NXOMC-4^N#S^^>0:*:5N5P['T7UHKHGG"IZG%@=3AN6CRG$X(B[0H.V
MM & 4#-.762G6J6U&(GX@#DY0AH!H 8ZE!2O:8QG(67NX=UE6KGCV/HU^>#U
M@2@'';;Q*M%ZNHH)C8:LW:37=[#VJ:!\NV+3>#\ZE@S"S;<B12L'>!(]U(D;
M9Z\K]P3$"--OZV.HQ$(VS<D69"/D&JUI$$ X'L:I"Z]9O<_!?G-S5I AC/-%
M>D!7S(US\*U=2+8T Q3<NS2^ST]X>]GL1YZ"@YLK5H/O>I8N>-%O[5SXL<&H
ME0XYEV@'='C[;Q+<;$UNPWRY8I:WA>$=/'_>DX S:+AA$IT7EP;4=K6O)@V#
MNW-I!O[] =:H6YR;%^1OC30#9^W3-%5!W(NEX17K:"N!H!C*(U!=?A>O RT/
M!N$7UUO%--"7Y(.P!/I(F9[ A%2H3(O[H6UV\, 5I6,KZ/< 64N?%SR/O <8
M7%4I<')EJEP0XM0Y<S9=[B:SAK0(P\Q:>^MC1P:?+.73[9ZU9F6N06;M*G_-
MU;/6/UG'%DC!4W.=Z: ]JPN-W2[D&S)PXO @UH(%,8Z!TL]4U[R_QYG(S5MD
ML%77KG50>^MZZE]C@7.A2MCS1C#?P.RV*MIU%IMV <%"X2!K1Y_(0<[N"Q<&
M[^TV$90X\(VYB+.5TT1)-[V(TXQ\0#)$(\Z]E2PT7Q9!-=[WO:,7K'>*2](#
M:BR$O@]"XSSJK1-@A!7">K22.U!&^M:>Y?>(@U5OV#,F'%P:C*#A&C?86/O1
M8<*;%$4-K8>N$+KRW15+$!.49:Y$2EE0-C)LRBS]W3!QB-!@Z]&^1H,F;$,T
M6] 9V+-.6?**S0-Q;%/E-5I).+)4NG/'SKER<3B/E5[LLKIQ,59L=%UG(7J]
MI?F2395W@VD1[YYN1(</W3GZ]"D8.OUH#'&9[R[/R.,HY/:ZR.=<"SE&2BC,
MR(]WF6U$^3MX4UH*#]I$?;VU6['A *GJ,IU1M9>YXX8C\2S*ER7@F<!/%ZOL
MS#@2.,)_HB:WRHG1CW<5[<#>-ECL* ?(,%B;^M( RU6YI#<9!HNI1#XILH:>
MD(0]];.XQ+#%JIXXG@_)F*9=GEZ83G9MTBM%TY#BJ:TZVS)0HK&<%SZHN;%S
M^SP 36]4,#DS=:\$(1MSHEDO_&M2-88K\@,M#)R?B:1+"D>9JET,P@YC(S4;
M)Q4<LEDLF<W$IG3N G)8$\8?DJN*0=!7M=IGSOFON/^JJ0[(T9%%&.MC)S%$
MDH6$+M!XG28N.8_Q"MI=PB:@10!:NXT 6O^=5;1XM2I-JZN3-"]%#@/#K"?Q
M;$;M*C9O((S>0;?-8ID5:PM\BL^8LT#.TR#D[]:HYOOH+XY# ?"NAWLGB-%5
MK4G)X0XC.Z5*)[^R=M-M-/T7 ;#SD]6D&U6YFFO&1V*9K]$)&(QQT4*3Q!4;
M!$>)L&DJ:D\[[X A%7&0%J6HWA31Y%&0+0X[F48@KG_ZQCK^=Q&JNMOHQXN'
ME]9BT4]NKUR"&,WB2^3>MV:EUOT#T>@]% 7I\(Y-)J_+(@OY,2@M/:U]63&V
M%_V+'0%(4RJ_VN6 UXLAH9IW..6.VE3.QMXYCU+/DIH)+LK;YV &,B':E<>C
MZ#*/;+*?W62RH^"?6UL_7?/JH%2R_112&R==M'7.TBK%!^D=48VI)WU8(6"F
M9A93Z4[G4Y))7Q+D&U&OB%M%?2Z>,1VTPK-YI?F\R'R"A^K *[AEMY?#]SNQ
M]YVXM_/O5TGW0I"P<ACR0:WJ/*Y\@AR%UBPA:^O%<U'AP])S7<K@3@,>5+&I
MA[(&T/LO/L<)&5;AW((-U4&H>Z6ASH""15H3(H_4:(UM3(AQ!9;3H2_Z]"Z^
M)*R"4,(S\'T2G2'&D+CHX2V.0]YKYV+=B3RR*W25&8>O11Z7DNTG\T6PN45N
M$T#]!2[SOL%MK&#,L)[+.)$ BB88(B)+(DE5: T';>S:-#XH:JEE8O*/VMZR
MVFH1BH2ZOH@S-J_+WPUTW#DEFXY?9P,+T<!";'P<9N$,<).A74%GJ83*BZ[.
M:R"MV- 6\2*^4V5/RO-U\5;$EB))<]+R),6A0SO@DR0B56@U+29&?<]69>A6
MX'*RKE)DV$'?*)RTB1T3,OB"D<&WG7'9*=M!WWGNZ4T'3_=+QLKAB_C0[&LK
M1>4\,Y=# _7UC%=81[/<EB67!1O),+[JU.W;Q@KS@3LQ6P<[>&J\OK"E2-YL
MTWY-H?SBH0GE ;B< KD>,)90QHQ=%GVSKX.@[/3A(=(U)V_?2!N\8?^2T)?9
M*MFJF.'MWZ2@WW#%<BTO0]K3))Y)+6J5VS*VL(4I[-\(APCV32WCE#G 0>8
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MZX/D3#%/-T- =QS'3,XBI#,MX3RZA!D8]*AU'BDA#K+G3OM<VM^HV-V=JC9
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M#V? 0+O<4;&%$XZU7H#T>F.&44<<:+J%K8Q9V_GU6KG>L6RNS$%5GZ1S.G]
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M-FIOL#;J*XPUK\VA&B8X6IDXB=G<T5TPFU+_](KX=Q0FIQHV6*N.(W[&1%#
MU# 5$7'_=DQF@7EN[(NXL-QY$O?35N_CO,U\D0W144"_8)I(%2>_\-)6PL6
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M7XM7^QS?D2CTPY1]G_W(+CAHZ$4*4F9!,45(T !?W<X5NT9G$[B&A/F^'8G
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ML[MEO/87\C[7F&,92TQC7'Z#0GY;A]_,9K7[Y&:@6B@?$)[OK64U^._KHW,
M>9_+X#_*\Q7FK=/@A-LS88&#3T:3Q,/R8>FF4_+<O;23L+:$5^(%^;7S;47^
MD%_3_OP_4$L! A0#%     @ "8)P5TN%\BI6%   8WD  !$
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H82TR,#(S,3$Q-%]P<F4N>&UL4$L%!@     %  4 1P$  $F\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
